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 Few studies have comprehensively investigated the validity of self-reported 
hypertension (HT) and assessed predictors of HT status in the stroke belt. The purpose of 
phase I of this study aims to evaluate self-reporting as a valid tool to screen large study 
populations and determine predictors of congruency between self-reported HT and 
clinical measures.  
Community Initiative to Eliminate Stroke project (n=16,598) was conducted in 
two counties of North Carolina in 2004-2007, which included collection of self-reported 
data and clinical data of stroke-related risk factors. Congruency between self-reported 
hypertension status and clinical measures was based on epidemiological parameters of 
sensitivity, specificity and predictive values. McNemar’s test and Kappa agreement levels 
assessed differences in congruency, while unadjusted odds ratios and logistic regression 
determined significant correlates of congruency.  
Sensitivity of self-reported HT was low (33.3%), but specificity was high 
(89.5%). Prevalence of self-reported HT was 16.15%. Kappa agreement between self-
report and clinical measures for BP was fair (ĸ = 0.25). Females, whites and young adults 
were most likely to be positively congruent, whereas individuals in high risk categories 
for total blood cholesterol, LDL, triglycerides and diabetes were least likely to be 
accurate about their HT status. Self-report HT information should be used with caution 
for epidemiological investigations. 
 
 
 The purpose of phase II of this study was to evaluate demographic sub-groups, 
self-reported health information and clinical measures as predictors of uncontrolled 
systolic and diastolic hypertension among individuals taking blood pressure lowering 
medications. Systolic hypertension is the most common form of hypertension among 
older individuals. Inadequate controls of systolic blood pressure have been largely 
attributable for poor control of overall hypertension rates. The National Heart Blood 
Pressure Education Program’s guidelines for management of hypertension emphasize the 
importance of controlling isolated systolic hypertension in older individuals.  
The Community Initiative to Eliminate Stroke was a stroke risk-factor screening 
and reduction/prevention project conducted in two North Carolina counties. The initiative 
collected self-reported information such as personal history of atrial fibrillation and 
clinical measures, such as blood pressure levels, among other cardiovascular and stroke 
risk factors. Statistical modeling of predictors was based on odds ratios and logistic 
regression analyses.  
Of the 2,663 participants, 43.5% and 22.8% had uncontrolled systolic and 
diastolic hypertension, respectively. African Americans were more likely to have 
uncontrolled systolic or diastolic hypertension as compared to whites. Similarly, 
participants older than 55 years of age were more likely to have uncontrolled systolic 
hypertension compared to younger individuals. Regression analyses indicated that race 
(OR = 1.239, p = 0.00), age (OR = 1.683, p = 0.00) and non-adherence with medications 
(OR = 2.593, p = 0.00) were significant predictors of uncontrolled systolic blood pressure 
levels. Based on the recommendations made by national guidelines and our findings, 
 
 
future interventions should focus on management of systolic hypertension among older 
individuals and African Americans to increase the overall control of hypertension. 
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CHAPTER I 
INTRODUCTION 
 
 
Heart disease is the leading cause of death for both men and women in the United 
States (U.S.) followed by cancer and stroke.
1
 The most common type of heart disease in 
the U.S. is coronary artery disease (CAD), also known as coronary heart disease (CHD).
1, 
2
 Collectively, cardiovascular diseases (CVD) which includes, hypertension, CHD and 
stroke have been the leading causes of death in the U.S. since 1900.
3
  
The overall prevalence rate (for both sexes) of CVD in 2006 was 36.9% for 
individuals aged 20 years or older. The prevalence rates of CVD among males and 
females aged 20 years and older were 37.9% and 35.7% respectively with the highest 
prevalence reported for both non-Hispanic black males and females aged 20 years and 
older at 44.6% and 46.9% respectively.
4
  
A study conducted by the American Heart Association found that Hispanic 
women were twice as likely to help someone lose weight or add physical activity in their 
daily routine in the last 12 months compared to non-Hispanic whites and non-Hispanic 
blacks. Furthermore, physician encouragement was one of the most cited reasons by 
Hispanic women that prompted them to take preventive action more often than non-
Hispanic white women.
5
 Hispanics were also found to be more likely to be non smokers 
compared to non-Hispanic whites and non-Hispanic blacks.
3 
2 
 
In 2006, the overall annual death rate (per 100,000) due to CVD was 262.5, 306.6 
for white males, 422.8 for black males, 215.5 for white females, and 298.2 for black 
females.
4
 Approximately, half of the deaths for women in 2006 were due to heart 
disease.
1 
When examined spatially, we see stark differences between regions across the 
U.S. The highest age-adjusted average annual deaths per 100,000 for adults aged 35 years 
and older is in the southeastern counties of the U.S. 
 
The trends over time however have been promising. There has been a steady 
decline in CVD death rates by 26.4% from 1995-2005 with a 9.5% decline in actual 
number of CVD deaths per year.
4, 6
 Although the CVD death rates have been declining in 
the past decade the burden of the disease still remains high. Based on mortality data from 
2006, approximately 2300 Americans die of CVD each day, an average of 1 death per 38 
seconds. In 2006, although the average life expectancy was 77.7 years, 33% of deaths due 
to CVD occurred before the age of 75 years. In 2006, 1 in every 2.9 deaths in the U.S. 
was caused due to CVD.
3, 4, 6
  
According to the Framingham Heart Study (FHS), CHD is the most common type 
of CVD in the U.S. and accounts for more than half of all CVD related events among 
men and women aged 75 years and younger.
7 
The lifetime risk of developing CHD after 
40 years of age is higher among men (49%) compared to women (32%).
8
 The 
Atherosclerosis Risk in Communities (ARIC) study reported that, the average age-
adjusted CHD incidence rates per 1000 person-years for participants between 45-60 years 
of age, were highest among white men and black men (12.5 and 10.6 respectively) 
compared to white women and black women (4 and 5.1 respectively).
9 
3 
 
The National Health and Nutrition Examination Survey (NHANES 2003-2006), 
analyses found that the total prevalence of CHD in 2006, among U.S. adults aged 20 
years and older was 7.9%. CHD prevalence is higher among men compared to women 
and highest among non-Hispanic white men (9.4%) compared to non-Hispanic black men 
(7.8%), and non-Hispanic black women (8.8%) compared to non-Hispanic white women 
(6.9%).
6, 10
 Preliminary data findings from the ARIC study and Cardiovascular Health 
Study (CHS), estimate that approximately 785,000 Americans will suffer from a new 
coronary attack and 470,000 will have a recurrent coronary attack.
3
 
 
In 2006, the overall CHD death rate was 134.9 per 100,000, with the highest rate 
reported for black men. In 2006, CHD-specific mortality rates/100,000 were 176.3 for 
white males and 206.4 for black males; and 101.5 for white females and 130.0 for black 
females.
4, 6
 The overall CHD death rates have decreased by 59% from 1990-1999, and 
annual death rate due to CHD declined by 36.4% from 1996-2006. But CHD still remains 
the largest major cause of death in the U.S. accounting for approximately 1 in 6 deaths in 
2006.
2, 3, 4, 11
 It is estimated that 34% of individuals who suffer from a coronary attack i.e., 
heart attacks and angina caused due to an underlying CAD and 15% of individuals who 
suffer from myocardial infarction (MI) i.e., heart attack as a result of interruption of 
blood supply to the heart muscle, in a year will die of it.
3
 A study investigating lifetime 
risk of CHD for participants involved in the FHS found that there was little or no change 
in the overall distribution between 10-year risk i.e., ages 40, 50, 60 and 70 for developing 
CHD.
8
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 Stroke is the third leading cause of death and the leading cause of disability in the 
U.S.
1
 In 2006, the prevalence rate for both sexes aged 20 years and over was 2.9% with a 
higher prevalence rate among women (3.2%) compared to men (2.5%). Approximately, 
795,000 people suffer from a new or recurrent stroke and overall, 87% are ischemic, 10% 
are intracerebral hemorrhage, and 3% are subarachnoid hemorrhage strokes.
12
 On an 
average 1 stroke occurs every 40 seconds in the U.S. Geographically, the stroke-related 
death rates are higher in the Southeast and Midwest regions of the U.S. compared to the 
Northeast.
13
  
The stroke incidence rate is higher among younger men compared to younger 
women but this pattern does not hold at older ages.
12
 Data analysis from the ARIC study 
and Warfarin-Aspirin Symptomatic Intracranial Disease Study (WASID) trial have 
shown that blacks have twice the risk of first-ever stroke compared to whites.
14
 The age-
adjusted stroke incidence rates in black men aged 45 to 84 years is 6.6 per 1000 
population, 3.6 in white men, 4.9 in black women, and 2.3 in white women.
12
 
Approximately 39% of this racial discrepancy has been attributed to disparities in 
community socioeconomic status.
15
 An increased incidence rate and racial disparity in the 
occurrence of first-ever stroke is also seen among Mexican Americans compared to non-
Hispanic whites. According to Basic Attack Surveillance in Corpus Christi (BASIC, 
NINDS), authors found that the crude cumulative incidence of stroke was 168/100,000 in 
Mexican Americans compared to 136/100,000 in non-Hispanic whites. The study also 
found that the Mexican Americans had twice the risk (relative risk = 2.04) of ischemic 
stroke at younger ages (45-59 years) compared to non-Hispanic whites.
16
 Similar results 
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were demonstrated in other studies emphasizing the racial disparity in first ever ischemic 
stroke incidence among Mexican Americans and blacks compared to non-Hispanic 
whites.
14, 17 
In 1980, the National Heart, Lung, and Blood Institute (NHLBI) examined the 
age-adjusted stroke mortality data in each state and found that, eleven states had stroke 
mortality rates higher by more than 10% than the national average. Of these eleven states, 
ten states formed a cluster in the southeast region of the U.S. NHLBI coined the term 
‘stroke belt’ emphasizing the burden of stroke in these states of the U.S. and 
consequently funded 11 pilot projects in 1991 to reduce the burden of stroke in these 
eleven states. Although, black men and women have higher incidence rates and mortality 
rates of stroke in the U.S., it was observed that white men and women also had higher 
incidence and mortality rates in the southeast region of the U.S. Therefore, race alone 
could not be attributed for the disparity of stroke incidence and mortality in this region.
18
  
Several studies have investigated the association between stroke risk factors, 
migratory patterns, occupational structure and mortality rates. These studies found that, 
even after adjusting for stroke risk factors, the mortality rate due to stroke was highest in 
the southeast parts of the U.S.
19, 20, 21, 22
 This geographical pattern of stroke incidence and 
mortality, observed since 1960s, has evolved and changed considerably in the last 25 
years. For example, a majority of counties in the coastal states of North Carolina, 
Georgia, South Carolina and Alabama reported high stroke mortality rates in 1962. Of 
these, three states were coined as the ‘stroke buckle’ i.e. states with the highest stroke 
mortality rates compared to other states of the stroke belt. Since then, in 1988 the high 
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stroke mortality rates had shifted to counties in the Mississippi delta and the Ohio River 
valleys.
19, 23
  
Previous hypotheses such as physical properties in the environment of the 
southeast region, climatic conditions, softness of water, deficiency of trace elements in 
the soil etc. have not been confirmed and have failed to explain the stroke belt 
phenomenon.
19
 Therefore, the authors suggest development and exploration of newer 
hypotheses that will allow researchers to focus on  factors such as accuracy of diagnosing 
and reporting stroke, social and economic conditions, the prevalence of risk factors
 
for 
stroke, the direction of migration patterns, the access and quality of health care 
systems.
19, 20 
The risk factors of CVD are mainly divided into three categories as follows: 
A. Biological indicators include: 
1. High blood pressure (hypertension) – is increased pressure exerted by the 
blood on the walls of the arteries which will eventually increase the risk of 
CHD and stroke. Smoking, alcohol use and physical inactivity are some of the 
major risk factors that lead to high blood pressure. More than often, there are 
no symptoms of high blood pressure and it is often referred to as the ‘silent 
killer’.  
2. High blood cholesterol – leads to the deposition of fats in the arteries that may 
develop into a plaque. This plaque leads to the development of atherosclerosis 
that will eventually hinder blood flow to parts of the body leading to CHD and 
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stroke. Diets high in cholesterol, physical inactivity and family history are 
some of the major risk factors of high blood cholesterol levels.  
3. Personal history of heart diseases (example: coronary heart disease can lead to 
stroke).  
4. Diabetes mellitus (high blood glucose levels) – tend to exacerbate high blood 
pressure and cholesterol levels in the blood.  
5. Overweight and obesity – leads to increased blood cholesterol levels, elevated 
blood pressure levels and development of diabetes mellitus.  
6. Previous history of transient ischemic attack (TIA), and sickle cell disease 
(associated with ischemic stroke). 
B. Behavioral indicators include: Tobacco use (smoking), physical inactivity, high 
cholesterol diet, and alcohol use. 
C. Hereditary indicators include: Family history of CVD and stroke. 
The aforementioned risk factors may act synergistically to cause heart disease and 
stroke.
24
 A study investigating three prospective cohort studies reported that 90% of CHD 
patients have a prior exposure to at least one of the following risk factors which include 
high blood pressure or current medication with BP lowering drugs, high total blood 
cholesterol levels or current medication with cholesterol lowering drugs, current cigarette 
use, and clinical report of diabetes (high blood glucose levels).
24
  
INTERHEART, a case-control study conducted in 52 countries reported that 
optimization of nine risk factors (cigarette smoking, abnormal blood lipid levels, 
hypertension, diabetes, abdominal obesity, a lack of PA, low daily fruit and vegetable 
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consumption, alcohol overconsumption, and psychosocial index) that are easily measured 
and modifiable, could lead to a 90% reduction in the risk of an initial MI. These results 
were consistent for both men and women across different geographical regions.
25
 The 
CHS study was conducted in four communities: Forsyth County, NC; Sacramento 
County, CA; Washington County, MD; and Pittsburgh, PA) of the U.S. The main goal of 
the study was to investigate risk factors associated with onset and course of CHD and 
stroke. The researchers of the CHS study found that subclinical CVD was very prevalent 
in older adults aged 65 years and over and the risk of CHD increased dramatically among 
participants with hypertension and/or diabetes mellitus.
26
 According to the Prospective 
Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER) trial, 2 
multi-component behavioral interventions significantly reduced the 10-year CHD risk 
among individuals with pre-hypertension or stage I hypertension.
27 
Several research studies funded by NHLBI such as FHS, CHS and Honolulu 
Heart Program (HHP) have shown that blood pressure is a strong determinant of CHD, 
ischemic stroke and intracranial hemorrhage. The lifetime risk of stroke is doubled in 
individuals with high blood pressure compared to individuals with a blood pressure level 
of less than 120/80 mmHg. Atrial fibrillation alone will increase the risk of stroke by 
fivefold throughout all ages.
28, 29
 Cigarette smoking doubles the risk of ischemic stroke 
among smokers compared to non-smokers.
3
 Diabetes mellitus also increase the risk of 
ischemic stroke, particularly in blacks before the age of 55 years and in whites before the 
age of 65 years.
30
 According to the Framingham Offspring Study, detection of silent 
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cerebral infarct was strongly associated with Framingham Stroke Risk Profile score, 
hypertension, and atrial fibrillation among other factors.
31
  
 According to NHANES data (1999-2004), women between ages 45-54 years are 
more than twice as likely as men to suffer from stroke.
32
 Women’s Health Initiative 
(WHI), a randomized trial found that estrogen and progestin contained in hormone 
replacement therapy increased the risk of ischemic stroke by 44% among post-
menopausal women.
33 
The increased risk was evident in women of all age groups, with or 
without hypertension and prior history of CVD. An early increase in overall stroke rate 
and increased rate of fatal stroke was reported in the first six months of therapy with 
estrogen alone among women with a mean age of 71 years.
34
 Other analyses from the 
WHI study have also shown that hormone replacement therapy that includes estrogen and 
progestin or estrogen alone does not reduce the risk of ischemic stroke among 
postmenopausal women, generally healthy women and women with established CVD.
33, 
35
 Early menopause, i.e. menopause before the age of 42 years, doubles the risk of 
ischemic stroke compared to women in different age groups.
36 
Collectively, cardiovascular diseases (CVD) and stroke are the leading causes of 
death in the United States and are included among the focus areas (focus area 12) in 
Healthy People 2010.
37, 38
 Hypertension (HT) is one of the chief risk factors leading to 
the development of CVDs and stroke in the U.S.
37
 According to the seventh report of the 
Joint National Committee on Prevention, Detection, Evaluation and Treatment of High 
Blood Pressure (JNC), worldwide prevalence of hypertension is estimated to be 
approximately one billion and 7.1 million deaths may be attributable to hypertension. The 
10 
 
World Health Organization reports that systolic blood pressure levels greater than 115 
mmHg (normal: less than120 mmHg) may be responsible for 62 percent of CVD and 49 
percent of ischemic heart disease (IHD), one of the CVD’s.
39
  It is important to note that 
HT is not only a component of CVD but also an isolated risk factor for the development 
of other CVDs.
11 
 
CHAPTER II 
 
REVIEW OF HYPERTENSION LITERATURE 
 
 
Introduction 
 
HT is defined
3
 as – systolic BP level of 140 mmHg or more or diastolic BP level 
of 90 mmHg or more or taking anti-hypertensive medications or having been told by a 
physician or other health professional that one has HBP at least twice. One in three 
Americans suffer from HBP.
40
 Approximately 33.6% of adults in the U.S. aged 20 years 
and over suffer from HBP in 2006 which include 34.4% males and 32.6% females.
3
 
According to NHANES data, men have higher rates of HBP compared to women until 
the age of 45 years. The prevalence rates are similar for both sexes between the ages of 
45-54 years, after which a much higher percentage of women have HBP compared to 
men.
41
 Furthermore, HBP is more prevalent among women who are taking oral 
contraceptives and are obese or overweight compared to women who are not.
42
 
NHANES data (2005-2006) reported that 29% of Americans who were 18 years 
of age and over had HBP. Pre-hypertension was prevalent among 28% of the U.S. adults 
and data findings suggested that 7% of those who had hypertension were never told about 
their condition. Among those who suffered from HBP, 78% of U.S. adults were aware of 
their condition and 64% of those were taking antihypertensive medications. 
Approximately 68% of those who were taking some form of HBP lowering medications, 
had their BP under control.
43
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A study that analyzed data from National Health Examination Survey (NHES), 
Hispanic Health and Nutrition Examination Survey (HHANES), NHANES and NCHS 
surveys conducted from 1963 to 2000 found that pre-hypertension and HBP prevalence 
trends increased by 2.3% and 1% respectively between 1988-1999 among children and 
adolescents aged between 8-17 years. An increase in abdominal obesity prevalence after 
1988 was partially attributed to this increasing trend.
44
  
The prevalence of HBP is highest among blacks in the U.S. The prevalence of 
HBP has significantly increased for both blacks (35.8% to 41.4%) and whites (24.3% to 
28.1%) respectively from 1988 to 1994 through 1999 to 2002. The prevalence of HBP is 
specifically high for black women at 44%.
45
 Blacks develop HBP earlier in life as 
compared to whites and have average BP levels much higher than whites. Therefore, 
blacks have 1.3-times greater rate of nonfatal stroke, a 1.8-times greater rate of fatal 
stroke, a 1.5-times greater rate of death due to heart disease and a 4.2-times greater rate 
of end-stage kidney disease compared to whites.
39
 Research and data have shown that 
blacks with the highest rate of HBP are more likely to be middle-aged or older, less 
educated, overweight or obese, lack physical activity and more likely to suffer from 
diabetes mellitus. Blacks with the lowest rate of HBP are younger in age but interestingly 
tend to be overweight or obese. It has also been observed that blacks who have 
uncontrolled HBP or are not taking any anti-hypertensive medications are usually males 
who are young and do not have frequent contact with a physician.
45, 46 
 Findings from the Reasons for Geographic and Racial Differences in Stroke Study 
(REGARDS) of the NINDS conducted between 2003 – 2007 suggested that racial 
13 
 
disparities  with regard to the control of HBP continue to exist with the odds of control 
being 27% lower in blacks than whites.
47
 The 2008 National Health Interview Survey 
(NHIS) found that black adults who were 18 years of age and older were more likely to 
be told on 2 or more occasions that they have HBP compared to other racial/ethnic 
groups.
10
 Furthermore, analysis of the combined NHIS data from 2000 and 2002, showed 
that black Hispanics were more likely to have HBP compared to white Hispanics and 
non-Hispanic blacks had the greatest risk of developing HBP. It was also reported that 
higher income and highly educated black Hispanics were still at a greater risk of 
developing HBP compared to low income and less educated white Hispanics.
48 
The ARIC study (NHLBI) suggests that HBP among blacks, especially in black 
women is a strong predictor of CHD.
49
 The good news is that the seventh report of the 
JNC found that the age-adjusted mortality rates for CHD and stroke have lowered from 
60 percent to 50 percent due to an increase in diagnosis and treatment of hypertension by 
blood pressure lowering medications. Although the mortality rates have declined by 10 
percent, the Framingham Heart Study researchers found that the lifetime risk for 
hypertension among non-hypertensives after the age of 55 years is approximately 90 
percent for both men and women in the U.S.
39
 In 2006, the overall death rate due to HBP 
as a primary or contributing cause was 17.8 with the highest rate reported among black 
males (51.1), black females (37.7), compared to white males (15.6) and white females 
(14.3). 
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Risk Factors of Hypertension
 
The risk factors for hypertension are divided into non-modifiable (individuals 
who are born with certain attributes that cannot be changed/altered) and modifiable 
(individual and environmental behaviors and attributes that can be modified/changed) 
risk factors.
 
Non-modifiable risk factors include: (a) age - lifetime risk of developing 
HBP increases with age; (b) ethnicity - blacks are more prone to develop HBP compared 
to other ethnic groups; (c) family history of HBP - Individuals with a known history of 
HBP within the family are more prone to develop HBP compared to those with no family 
history of HBP; and, (d) genetic factors.
 
Modifiable risk factors include: (a) less 
education
; 
(b) low SES; (c) overweight or obesity; (d) lack of physical activity; (e) 
tobacco use; (f) physiological stressors; (g) high dietary sodium intake;
 
(h) low potassium 
dietary intake; and, (i) excessive alcohol use.
 
Types of Hypertension 
1. Essential Hypertension: also known as primary hypertension refers to HBP for 
which no cause can be found. A majority of U.S. adults (90-95%) suffer from this 
type of HBP in which several modifiable and non-modifiable risk factors 
contribute synergistically to the development of HBP. 
2. Non-essential Hypertension: also known as secondary hypertension refers to HBP 
caused due to certain temporary and controllable conditions such as pregnancy 
and/or use of certain medications. A few chronic conditions such as hormonal 
diseases, renal diseases or head injuries can also lead to the development of 
15 
 
secondary HBP. This type of HBP affects approximately 5-10% of the U.S. 
population. 
Management of Hypertension 
The two aspects of management of HBP include (1) pharmacological therapy that 
aims at reducing and controlling one’s systolic or diastolic or both levels of BP, and (2) 
public health management that aims at increasing awareness about HBP and its risk 
factors, early detection and prevention via modification of environmental attributes and 
unhealthy risk behaviors and primary prevention and management via lifestyle changes. 
Pharmacological Management 
 Over the past several decades, there have been numerous drug trials and advances 
in the management of HBP. A wide range of anti-hypertensive drugs are now available 
that can be used alone or in combination with other anti-hypertensive drugs to control 
HBP. The JNC reports that more than two-thirds of individuals suffering from HBP will 
require more than one anti-hypertensive drug to control HBP (SBP < 140 mmHg and 
DBP < 90 mmHg).
50, 51, 52, 53, 54
 The Antihypertensive and Lipid-Lowering Treatment to 
Prevent Heart Attack Trial (ALLHAT), conducted in 1994, found that only 30% of 
participant’s BP were controlled by one drug as compared to 60% of participants whose 
BP were controlled by the use of two or more anti-hypertensive agents.
55
 Thiazide-type 
diuretics have shown success in most placebo-control outcome trials and form the basis 
for anti-hypertensive therapy. The diuretics have been proven to reduce CHD, heart 
failure and stroke risk, among other CVD events.
55, 56, 57, 58, 59
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Other randomized controlled and clinical trials (European Trial on Systolic 
Hypertension in the Elderly (Syst-EUR),
60
 Heart Outcomes Prevention Evaluation 
(HOPE) Study,
61
 The European Trial on  Reduction of Cardiac Events with Perindopril in 
Stable Coronary Artery Disease (EUROPA) study
62
 etc.) have shown success in 
controlling HBP and include anti-hypertensive agents such as loop diuretics, potassium-
sparing diuretics, Aldosterone-receptor blockers, beta-blockers, combined alpha and beta-
blockers, Angiotensin-converting enzyme inhibitors (ACEI), Angiotensin II blockers, 
calcium-channel blockers, Alpha-1 blockers, Alpha agonists and directly acting 
vasodilators. 
JNC report provides recommendation with regards to the pharmacological 
treatment of HBP. As per JNC report, thiazide-type diuretics are recommended as first-
choice drugs in the line of treatment of HBP. This recommendation is based on the 
evidence generated in multiple drug trials, which have shown increasing efficacy and 
effectiveness of thiazide-type diuretics compared to other drug options in preventing 
CVD-related events.
39
 The ALLHAT study found that there were no differences between 
thiazide diuretic (chlorthalidone), ACE-Inhibitor (lisinopril) and calcium-channel blocker 
(amplodipine) with regards to primary CHD outcomes and mortality. The study also 
reported that individuals treated with either calcium-channel blocker or ACE-Inhibitor 
had greater incidence of heart failure compared to individuals treated with a diuretic.
64
 
Thiazide-type diuretics have been proven to be generally safe and inexpensive compared 
to other anti-hypertensive drugs.
54, 63, 64 
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Public Health Management of HBP  
 There have been substantial improvements from a public health 
perspective in raising awareness, treating and controlling HBP levels. But these 
improvements have not been exemplified in the total population. For example, data from 
the National Health Examination Survey (NHES) conducted between 1976 and 2003, has 
shown that approximately one-third of the U.S. population who have HBP are unaware of 
their HBP, more than 40% of individuals with HBP are not taking any BP-lowering 
medications and two-thirds of the population who are on anti-hypertensive treatment are 
not being controlled to BP levels of 139/89 mmHg or less.
39
  
At the same time, the decline in CHD and stroke associated mortality rates have 
slowed down while hospitalizations (see figure 10) related to heart failure have increased 
in the past decade.
65
 One study suggested that the decline in CHD mortality was 
attributable to medical therapies and adoption of lifestyle and environmental changes that 
led to changes in CHD risk factors in the population.
66
 Moreover, authors from another 
study also found that there was an increased usage of medical procedures such as cardiac 
catherterization, percutaneous transluminal coronary angioplasty, and bypass graft 
surgery that led to increased hospitalization rates between 1979 to 2005.
10  
In lieu of the fact that as age progresses, lifetime risk of an individual to suffer 
from HBP also increases, it is imperative to compliment HBP treatment strategies with 
public health interventions. As mentioned in the section ‘Risk Factors’, there are several 
modifiable risk factors of HBP that can be measured and controlled. These factors 
include excess body weight, lack of physical activity, lack of fruits and vegetables in the 
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diet, high dietary sodium and cholesterol intake, cigarette and alcohol use.
67
 JNC 7 has 
recommended a model guideline that includes management of HBP via lifestyle 
modifications and anti-hypertensive treatment. The recommendations focus on adjusting 
or modifying certain behaviors and reduction of BP levels to 139/89 mmHg or less. It has 
been shown that a small decrease in systolic BP by 5 mmHg, can lead to a reduction in 
CHD-associated and stroke-associated mortality by 9% and 14% respectively.
67, 68  
JNC recommends that initiation of therapy for HBP should begin with lifestyle 
modifications. These modifications include and are not limited to, reduction in sedentary 
activities such as watching TV or spending time online and playing video games, 
increasing physical activity to include moderate exercise for 30 minutes per day on most 
days of the week, reduction in dietary salt intake and inclusion of fruit and vegetable 
servings in everyday meals. The Dietary Action to Stop Hypertension (DASH) outlines 
recommendations for adoption of low sodium diet that promotes inclusion of fruits and 
vegetables in daily diets. DASH studies have shown that inclusion of heart health foods 
that are low in cholesterol and sodium have been very beneficial in promoting weight 
loss, reduction of BP in hypertensive individuals and reduction in low-density 
lipoproteins.
69
  
 The recommended lifestyle modifications lead to significant reduction in systolic 
BP which furthermore, reduces the risk of CHD-associated and stroke-associated events. 
If the lifestyle modifications do not reduce the HBP levels below 140/90 mmHg, 
thiazide-type diuretics should be started along with another drug to reduce HBP levels. 
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The multi-drug treatment should be complimentary to the continuation of maintaining 
healthy lifestyle and modifying unhealthy behaviors. 
 Based on the literature review above, the author has identified gaps primarily in 
two areas of public health research pertaining to CVD, stroke and hypertension. These 
gaps which are discussed in detail below will allow for exploration of alternative answers 
and help in formulating recommendations for future research and interventions 
concerning CVD, stroke and hypertension. The two areas of research that warrant further 
exploration and research are as follows: 
1. Self-awareness of one’s blood pressure status via validation and prediction of 
self-reported HBP status and its implications on future public health research and 
interventions. 
2. Demographic and clinical predictors of level of control of BP measures (systolic 
and diastolic) and its impact on HBP education in public health, clinical and/or 
pharmacological settings.
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CHAPTER III 
 
VALIDITY OF SELF-REPORTED HYPERTENSION STATUS AND 
PREDICTORS OF CONGRUENCY WITH CLINICAL MEASURES 
 
 
Introduction 
Hypertension (HT) is a silent killer affecting one in three U.S. adults.
1
 In 2010 it 
was estimated that HT cost the U.S. $76.6 billion in missed days from work and medical 
care, including medications.
2
 HT is a major risk factor for cardiovascular disease (CVD) 
and stroke, which are among the top three leading causes of death in the U.S.
3
 According 
to the Framingham Heart Study (FHS), the lifetime risk for developing HT after the age 
of 55 years is 90 percent for both non-hypertensive men and women.
4
 Since the inception 
of the National High Blood Pressure Education Program (NHBPEP) in 1972, there have 
been continued efforts to raise awareness, treat and control HT, unfortunately 
uncontrolled BP levels continue to remain high.
2, 5-7
 Therefore, it is imperative to enhance 
epidemiological surveillance and population-based public health strategies aimed at 
secondary prevention of HT and/or primary prevention of CVDs and stroke.  
Typically, surveillance activities involving HT and its associated risk factors 
require large populations and clinical measurements that can be very time-consuming and 
expensive.
5, 8-11 
Thus, the emphasis is placed on conducting small-scale, cross-sectional or 
cohort studies relying on self-reported information about one’s HT status.
5, 8-13
 These 
smaller-scale studies can be conducted at local or state levels and are practical, 
inexpensive and can be comprehensively assessed. Furthermore, results from these 
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studies, would enable health researchers and practitioners to design community-based 
interventions targeting populations in most need.  
In assessing self-reported data, it is important to pay particular attention to the 
validity of the information collected and how well this information reflects the clinical 
measures of BP levels.
5, 8-12, 14, 15
  Validity studies involve epidemiologic assessment and 
reporting of sensitivity, specificity, and predictive values. Few studies have evaluated the 
validity of self-reported information in the U.S., particularly at regional levels.
9, 11, 16
 
Even the previous studies that have assessed validity of self-reported HT status have been 
based on relatively small sample sizes.
10, 16-18
 Furthermore, very little is known about the 
predictors of congruency between self-reported information and one’s actual HT status. 
Although these studies have found mild to moderate sensitivity and high specificity, 
recommendations with regards to the utility of self-reported BP status as a valid tool to 
screen large numbers of individuals in a community-based setting have been mixed. Even 
guidelines and definitions for both self-reported and clinical measures of BP have 
evolved over the last three decades. Therefore, the interpretation of results in some of 
these studies becomes difficult in light of the current JNC 7 guidelines and definition of 
HT. 
The purpose of this paper is twofold: (a) to assess the validity of self-reported HT 
status compared to clinical measures of BP levels in a cross-sectional pool of participants 
from the ‘Community Initiative to Eliminate Stroke (CITIES) project using the most 
current JNC guidelines; and (b) to determine predictors of the level of congruency 
between one’s self-reported information and actual BP measures. This assessment will 
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not only allow investigators to evaluate self-reported data as an expedient and reliable 
tool to screen large numbers, but also enable health professionals to design and 
implement targeted educational messages aimed at raising awareness of HT and its risk 
factors.         
Methods 
CITIES Project 
The CITIES project of North Carolina (NC) was a three-year project funded by 
the Office of Minority Health (OMH), DHHS and awarded to the Forsyth Medical Center 
(FMC) Foundation in formal partnership with the Moses Cone Health System (MCHS), 
the University of North Carolina at Greensboro (UNCG) and the North Carolina 
Agriculture & Technical State University (NC A&T). This initiative was implemented in 
two NC counties, Guilford and Forsyth, and targeted persons of color, low-income, and 
rural residents for whom English was a second language. The main components of the 
CITIES project were: (a) to screen individuals for stroke risk factors; (b) make 
recommendations and referrals as appropriate for identified risk factors; and (c) provide 
health education and health promotion activities to reduce the prevalence of stroke risk 
factors. 
Settings and Procedures 
Each medical center used a mobile unit and registered nurses (RN) to screen 
individuals at sites with preset appointments, such as churches, factories, health fairs, etc. 
and at sites with unscheduled appointments within the two respective counties. A total of 
19,621 individuals were screened for stroke risk factors in the CITIES project. A 
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convenient sub-sample was used to recruit individuals for this study. Participation was 
voluntary and each participant was included in this study if they were 18 years or older 
and signed the consent form. The RNs used a standard questionnaire that was divided 
into three distinct categories, including demographic information, self-reported stroke 
risk factors, and clinical and biomedical measurements of stroke risk factors.
19
 The 
participants were asked to self-report their hypertension status by answering the 
following question: “Do you suffer from high blood pressure and/or has a 
physician/doctor/nurse diagnosed you as a hypertensive?” Inclusion criteria was based on 
a ‘yes’ response to the HBP question. 
The RNs measured the blood pressure of each participant using an electronic 
machine – DYNAMAP, which was wet-tested and calibrated every week. A minimum of 
two measurements were taken in the seated position with the arms outstretched and the 
lowest BP reading was recorded. If the first reading was high, i.e., high systolic and/or 
diastolic BP, then BP was measured again after two minutes in the same arm. If the 
readings on the machine were found to be high on both occasions, then the registered 
nurses would manually measure the blood pressure twice in the other arm using a 
calibrated sphygmomanometer, and then record the lowest readings.  
All participants who had a BP measurement of 160 mmHg for systolic and/or 100 
mmHg for diastolic or higher were referred to an E.R. promptly to get their BP checked 
again. Other self-reported information included overweight status, smoking, exercise 
status, and use of BP lowering and lipid-lowering medications. All self-reported 
information was collected prior to collection of blood samples and recording of clinical 
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and biomedical measurements. Clinical and biomedical measurements included blood 
LDL, HDL, total cholesterol, triglycerides and glucose levels. Blood measurements were 
obtained using finger prick blood screening procedures. BMI was calculated based on 
height and weight measurements. The RNs also collected demographic information such 
as age, sex, education etc. from all participants. The project was approved by the 
respective Institutional Review Boards for all institutions. 
Statistical Analyses 
JNC 7 defines HT as having a systolic BP level of 140 mmHg or more and/or 
diastolic BP levels of 90 mmHg or more. Our gold standard i.e. possible diagnosis of HT 
in our sample was computed based on systolic, diastolic blood pressure levels and 
classification parameters of HT proposed by JNC 7.
4
 Thus possible diagnosis of HT was 
defined as systolic BP levels of 140 mmHg and/or diastolic BP of 90 mmHg or more. MS 
Access
©
 was used to input data, which was analyzed using PASW statistics software, 
version 18.
20, 21
 The final sample excluded individuals who were taking BP lowering 
medications in order to avoid confounding results. The participants’ demographic 
characteristics, self-reported information and clinical measurements were described using 
frequencies and percentages. Bivariate associations were calculated using cross-
tabulations to compare self-reported information (yes and no) from the questionnaire with 
possible diagnosis of HT (yes and no) based on BP measurements. The validity of the 
self-reported information was evaluated on the basis on sensitivity, specificity, and 
positive and negative predictive values. McNemar’s test was used to ascertain differences 
between positively congruent individuals and those who were not congruent. Kappa (ĸ) 
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scores were used to assess agreement between self-reported status and possible diagnosis 
of HT. A ĸ score of less than 0.20 was considered poor agreement, 0.20-0.40 fair 
agreement, 0.41-0.60 moderate agreement, 0.61-0.80 substantial agreement, and more 
than 0.81 as almost perfect agreement.  
The dichotomous outcome variable for congruency between self-reported 
information and clinical data was computed using the cross tabulations for self-reported 
and possible diagnosis of HT. Congruence between self-reported and measured BP was 
taken as a measure of being aware of one’s HT status, whereas disagreement between 
self-reported and measured BP was taken as a measure of being unaware of one’s HT 
status. Odds ratios and confidence intervals (CI) at 95% were calculated using standard 
procedures to assess determinants of positive congruency. Congruency, the outcome 
variable, was modeled as a function of independent variables including, demographic 
characteristics, self-report information and clinical measurements. Binary logistic 
regression and forward likelihood ratio method were used to evaluate statistically 
significant predictors of HT congruency. The statistical significance for all analyses was 
based on the conventional alpha level of significance of 0.05.  
Results 
Table 1 presents the demographic characteristics of the participants. A majority of 
the participants in the CITIES project were females. Approximately 50% of the 
participants were Caucasians. More than half (62.2%) of the participants were aged 41 
years or older. Approximately 60% of the participants reported an annual income of less 
than $35,000, while more than half of the participants had more than high school 
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education. Self-reported risk information is presented in Table 2. Almost 85% of the 
participants self-reported, ‘No,’ when they were asked: “Do you suffer from high blood 
pressure and/or has a physician/doctor/nurse diagnosed you as a hypertensive?” The 
results of the clinical measures of the participants are reported in Table 3. Less than one 
third i.e. 20.5% and 14.2% of the participants had systolic or diastolic hypertension in 
stages I or II respectively.  
Among those who self-reported as having HT, slightly more than half of the 
participants were confirmed to have clinical HT stages I or II for a positive predictive 
value of 51.2%. More than three quarters (80.3%) of the participants who self-reported as 
non-hypertensive were confirmed not to have a possible diagnosis of clinical HT stages I 
or II. Overall, the sensitivity of self-report for correctly identifying those who have HT 
was 33.31%, while the specificity, i.e., correctly identifying those who did not have HT, 
was 89.5% (see Table 4). The prevalence of HT in this sample was 16.15% (based on 
self-reporting) and 24.81% (based on clinical measures of BP). McNemar’s test showed 
that there was a statistically significant difference between those who were positively 
congruent and those who were not (p < 0.01). The overall ĸ score for agreement between 
self-reported and clinical measures of BP was 0.25.  
Unadjusted ORs showed that females had 1.366 times greater odds of being 
congruent and aware of their HT status compared to males (see table 5). Caucasians were 
found to be more aware of their HT status as compared to African-Americans. Similarly, 
younger populations (18 to 40-year-olds and 41 to 55-year-olds) were also more likely to 
be congruent for their HT status as compared to older adults. Those individuals who 
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reported, ‘no,’ when asked if they had personal and/or family history of CVD tended to 
be more aware of their HT status compared to those who reported the presence of a 
personal and/or family history of CVD. Additionally, individuals who self-reported that 
they did not have diabetes or high cholesterol had respectively 1.6 and 1.9 times greater 
odds of being congruent compared to those who said ‘yes’ in all of those situations. For 
individuals who had normal or optimum levels of blood cholesterol, LDL, HDL, 
triglycerides, and blood glucose levels, the odds was higher that they were aware of their 
HT status compared to those individuals whose levels fell into high risk categories. Those 
who had normal BMI levels (18.5 – 24.9999) had almost 2.5 times greater odds of being 
congruent than individuals who were obese.  
After controlling for other covariates, a multivariate logistic regression using 
stepwise likelihood ratio model found that gender (p = 0.00), race (p = 0.00), age (p = 
0.00), family history of CVD (p = 0.00), self-reported diabetes status (p = 0.02), total 
blood cholesterol (p = 0.00), HDL levels (p = 0.00), blood triglyceride levels (p = 0.00), 
and BMI (p = 0.00) were statistically significant predictors of congruency with 5% of 
variance explained by the final model (see Table 6). These results were similar to the 
bivariate associations (ORs) discussed above. Cross-tabulations and unadjusted odds 
ratios were conducted to further explore level of congruency between select groups of 
individuals that were found to be significant predictors. Approximately 4/5
th
 of the 
participants (88%) that were white females aged 18-40 years old were positively 
congruent i.e. more aware of their HT status (n = 3768).        
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Discussion 
 The investigators reviewed the validity of self-reported information of one’s HT 
status in comparison to clinical measurements of BP levels in two counties of NC. Our 
results indicate that the level of congruency between self-reported and clinical measures 
of HT is low. The sensitivity of self-reported HT status was only 33%. In comparison, 
other studies that have employed a heterogeneity of research methodologies to investigate 
validity, reported a moderate to high sensitivity of approximately 50-90%.
9-11, 13, 14, 16-18, 
22-26 
 Only one study, the Utrecht Health Project reported results similar to ours with a 
sensitivity of 34.5%.
15
 Conversely, the specificity of self-reported HT status of 89.5% in 
our sample was high and was similar to specificity reported in other studies.
9-11, 13-18, 22, 26
 
The results of high specificity are particularly encouraging, since it has been postulated 
that in the long-term new incident cases of HT will be eventually diagnosed upon long-
term follow-up.
5
  
We used McNemar’s test and kappa score classification to measure the strength of 
agreement between self-reported and clinical measures of HT.
27
 The overall ĸ scores 
indicated only fair agreement between the two in comparison to other studies that have 
shown a moderate to substantial agreement.
5, 9, 10, 12, 22, 26, 28
 Two reasons why validity of 
self-reported HT was low in our sample could be because HT has a less clear-cut 
diagnostic criterion in comparison to other diseases, like diabetes, fractures and breast 
cancer, and HT is a silent killer that does not present clinical signs and symptoms on a 
daily basis.
8, 15
 As a result, the clinical measures, diagnosis, short-term and long-term 
implications of having HT may not be easily perceived and understood by the patient. 
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Therefore, it becomes increasingly important for physicians to accurately assess, 
diagnose and treat HT and for health professionals to raise awareness of the condition 
among both physicians and patients.  
 We also found that certain sub-groups in our sample were more congruent, i.e., 
able to report their HT status more accurately compared to others. Females, whites and 
younger adults were more accurately aware of their HT status. Similarly, persons who 
self-reported as normal weight, without a personal or family history of CVD, and without 
diabetes were also generally more aware of their HT status compared to those who 
reported a history of CVD, diabetes and /or felt they were overweight or obese. Similar 
findings have been reported by Muhajarine et al.
29
 Interestingly, our analysis found that 
individuals who fell into high risk categories for blood cholesterol, LDL, HDL, 
triglycerides, glucose levels and/or BMI were least likely to be congruent compared to 
individuals who were found to be within normal limits for any of those levels. Based on 
these findings, it seems that individuals who feel that they are unhealthy based on their 
self-reported overweight and exercise status or those who have high risk factors for 
developing HT or any other CVD appear to be least aware of their HT status. One 
hypothesis for this occurrence could be that these individuals are less likely to see a 
physician for annual check-ups thereby falling into a vicious cycle of not knowing what 
their actual health assessment is, leading to a lack of awareness of clinical correlates of 
HT and CVD and its associated prevention strategies. These individuals then continue to 
engage in unhealthy behaviors and are thus less likely to change or modify lifestyle 
behaviors for the betterment of their health.  
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Giles et al. have found that individuals who had a preventive health care check-up 
in the last year were more likely to be aware of their HT status.
13
 This finding supports 
the notion that public health campaigns designed to raise awareness of HT and its 
correlates should also focus on encouraging individuals to access preventive care 
services, i.e., getting annual physical check-ups. The diabetes education and screening 
program conducted at Smith Island showed that participants became more aware of their 
health risks associated with diabetes, hypertension and high cholesterol as a result of the 
screenings and counseling offered during the screening services.
30
 Moreover, the follow-
up rates for annual clinic visits increased due to continued efforts to raise awareness and 
educate residents about these conditions. Although this program was focused on diabetes, 
interventions targeting HT could be modeled after the Smith Island program to raise 
awareness of the risk factors of HT and highlight the importance of periodic health 
check-ups.        
Conclusion 
Self-reported information for HT should be used only with great care as a 
screening tool in large, population-based studies. This study found that individuals who 
had a possible diagnosis of HT based on their clinical measures were likely to report as 
not having HT. Thus self-reporting could lead to an under-estimation of the prevalence of 
HT in our population. Several participant characteristics were identified as potential 
predictors of decreased awareness of one’s HT status including males, African-
Americans, those age 55 years and older and those who were in a high risk category for 
several HT and CVD correlates. Future interventions should employ strategies that 
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increase availability and encourage participation of individuals in preventative care 
services, including getting an annual physical. Although the diagnosis of HT is a more 
involved process, future research could focus on evaluating the accuracy of screening 
data as an indicator of actual diagnosis of HT. 
 
. 
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Tables 
 
Table 1: Demographic Characteristics of Respondents
1 
in CITIES 
Project, NC 2004-2007 
Personal Characteristics                Totals 
N (16,598) % 
Gender   
Male 5,747 36.3 
    Female 10,087 63.7 
Race   
    Caucasian 7,329 47.1 
    African American 6,758 40.7 
    Hispanic 514 3.3 
    Asian/Pacific Islander 456 2.9 
    Other 513 3.1 
Age   
     18 to 40 years old 5,965 38.0 
     41 to 55 years old 6,285 40.0 
     ≥ 56 years old 3,454 22.0 
Income    
     < $35,000 9,735 64.7 
     > $35,000 5,308 35.3 
Education   
     Less than High School 1,122 7.2 
     High School or GED 4,598 29.5 
     More than High School  9,859 63.3 
Ethnicity    
     Hispanic/Latino  514 3.3 
     Non-Hispanic/Latino 15,056 96.7 
1
 Totals do not sum to the sample size due to missing data. 
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Table 2: Self-Reported Characteristics of Respondents
1
 in CITIES 
Project, NC 2004-2007 
Self-Reported Characteristics                Totals 
N (16,598) % 
Personal h/o
2’’
 CVD   
Yes 701 4.2 
     No 15,897 95.8 
H/o Atrial Fibrillation   
     Yes 7,329 47.1 
     No 6,758 40.7 
Family h/o CVD   
     Yes 3,868 23.3 
     No 12,730 76.7 
Smoking Status    
     Yes 2,880 17.4 
     No 13,718 82.6 
Overweight Status   
     Yes 8,248 49.7 
     No 8,350 50.3 
Lack of Exercise Status   
     Yes  7,891 47.5 
     No 8,707 52.5 
Hypertension Status   
     Yes 2,555 15.4 
     No 14,043 84.6 
High Blood Cholesterol Status   
     Yes 2,771 16.7 
     No 13,827 83.3 
Diabetes Status   
     Yes 868 5.2 
     No 15,730 94.8 
Stress Status   
     Yes 3,726 22.4 
     No 12,872 77.6 
1
 Totals do not sum to the sample size due to missing data. 
2
 h/o – history of 
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Table 3: Clinical Characteristics of Respondents
1
 in CITIES Project, NC 2004-2007 
Clinical Characteristics                    Totals 
N (16,598) % 
LDL   
   Very High Risk (> 190 mg/dl) 297 2.3 
   High Risk (160-189 mg/dl) 892 7.0 
   Borderline High Risk (130-159 mg/dl)             2,646 20.7 
   Near Optimum/Above Optimum (100-129 mg/dl) 5,076 39.7 
   Optimum (< 99 mg/dl)    3,874 30.3 
HDL   
   High Risk (< 40 mg/dl) 4,072 26.1 
   Normal (40-59 mg/dl) 7,678 49.1 
   Preventive (> 60 mg/dl)  3,876 24.8 
Total Cholesterol   
   High Risk (> 240 mg/dl) 1,537 9.8 
   Moderate Risk (200-239 mg/dl) 4,214 26.8 
   Normal (< 199 mg/dl) 9,959 63.4 
Triglyceride   
   High Risk (> 200 mg/dl) 3605 23.0 
   Borderline High Risk (150-199 mg/dl) 2,696 17.2 
   Optimum (< 149 mg/dl) 9,378 59.8 
Blood Glucose   
   High Risk (> 200 mg/dl) 261 1.7 
   Moderate Risk (150-199 mg/dl) 472 3.0 
   Normal (50-149) 14,995 95.3 
BMI   
   Obese (>30) 5,318 34.0 
   Overweight (25-29.9999) 5,496 35.1 
   Normal (18.5-24.9999) 4,623 29.5 
   Underweight (< 18.5) 209 1.4 
Systolic BP   
   Hypertension Stage II (> 160 mmHg) 666 4.2 
   Hypertension Stage I (140-159 mmHg) 2560 16.3 
   Pre-Hypertension (120-139 mmHg) 7,079 45.0 
   Normal (< 119 mmHg) 5,428 34.5 
Diastolic BP   
   Hypertension Stage II (> 100 mmHg) 431 2.7 
   Hypertension Stage I (90-99 mmHg) 1,816 11.5 
   Pre-Hypertension (80-89 mmHg) 5,128 32.6 
   Normal (< 79 mmHg) 8,358 53.2 
Combined BP (Systolic and Diastolic)   
   Hypertension Stages I and/or II 1,519 9.7 
   Normal and/or Prehypertension 14,122 90.3 
   
1
 Totals do not sum to the sample size due to missing data. 
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Table 4: Self-Reported HT Status versus Clinical Diagnosis of HT
1
 
in CITIES Project, NC 2004-2007 
 
Test Characteristics  Clinical Diagnosis of HT 
Hypertensive Non-
Hypertensive 
Total 
Self-Reported (Yes) 1,298 1,239 2,537 
Self-Reported (No) 2598 10,568 13,166 
Total 3,896 11,807 15,703 
1
 Totals do not sum to the sample size due to missing data. 
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Table 5:  Bivariate Analysis – Determinants of HT Awareness (Positive Congruence) 
by Demographic, Self-Report and Clinical Characteristics in CITIES Project, NC 
2004-2007 
Participant Characteristics Odds Ratio 95% CI 
     Gender    
          Male (reference) -- -- 
       Female 1.366* 1.268, 1.472 
     Race   
       African American (reference) -- -- 
               
Caucasian 1.150* 1.065, 1.242 
     Age   
       > 55 years old (reference) -- -- 
               
41 to 55 years old 2.083* 1.903, 2.281 
               
18 to 40 years old 3.157* 2.857, 3.488 
  Income   
       > $35,000 (reference) -- -- 
       < $35,000 1.082 0.942, 1.101 
  Personal h/o CVD   
          Yes (reference) -- -- 
          No 1.738* 1.481, 2.039 
  H/o Atrial Fibrillation   
          Yes (reference) -- -- 
          No 1.473* 1.124, 1.929 
  Family h/o CVD   
          Yes (reference) -- -- 
          No 1.264* 1.164, 1.373 
  Smoking Status   
          Yes (reference) -- -- 
          No 0.977 0.888, 1.074 
  Overweight Status   
          Yes (reference) -- -- 
          No 1.426* 1.325, 1.536 
  Lack of Exercise Status   
          Yes (reference) -- -- 
          No 1.009 0.938, 1.085 
  High Blood Cholesterol Status   
          Yes (reference) -- -- 
          No 1.597* 1.459, 1.747 
  Diabetes Status   
          Yes (reference) -- -- 
          No 1.891* 1.638, 2.182 
  Stress Status   
          Yes (reference) -- -- 
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          No 1.034 0.950, 1.126 
  Total Blood Cholesterol   
          High Risk (reference)   
          Moderate Risk 1.199* 1.055, 1.362 
          Normal 1.582* 1.406, 1.781 
  LDL   
          Very High Risk (reference) -- -- 
          High Risk 0.932 0.699, 1.244 
          Borderline High Risk 1.120 0.859, 1.460 
          Near/Above Optimum 1.259 0.972, 1.631 
          Optimum 1.497* 1.152, 1.947 
  HDL   
          High Risk (reference) --  -- 
          Normal 1.323* 1.213, 1.443 
          Preventive 1.337* 1.208, 1.481 
  Triglycerides   
          High Risk (reference) -- -- 
          Moderate Risk 1.222* 1.094, 1.366 
          Normal 1.609* 1.476, 1.755 
  BMI   
          Obese (reference) -- -- 
          Overweight 1.260* 1.158, 1.371 
          Normal 2.211* 2.006, 2.438 
          Underweight 2.301* 1.579, 3.354 
  Blood Glucose   
          High Risk (reference) -- -- 
          Moderate Risk 1.122 0.819, 1.536 
          Normal 1.974* 1.532, 2.544 
* Significant at p < 0.05 
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Table 6: Logistic Regression – Predictors of Non-Congruency by Demographic, Self-
Reported and Clinical Characteristics in CITIES Project, NC 2004-2007 
Participant Characteristics β Odds Ratio (95% CI) p 
     Gender    
          Female (reference) -- -- -- 
          Male 0.329 1.389 (1.261, 1.530)* 0.00 
     Race    
          Caucasian (reference) -- -- -- 
               
African Americans 0.163 1.178 (1.069, 1.296)* 0.00 
          Hispanics/Latinos 0.313 1.367 (1.028, 1.817)* 0.03 
          Asians/Pacific Islander 0.152 1.165 (0.883, 1.537)  0.28 
          Others 0.145 1.156 (0.887, 1.507) 0.28 
     Family h/o
a
 CVD    
          No (Reference) -- -- -- 
          Yes 0.175 1.191 (1.078, 1.316)* 0.00 
     Diabetes Status    
          No (Reference) -- -- -- 
          Yes 0.214 1.238 (1.021, 1.281)* 0.03 
     Triglycerides    
          Normal (reference) -- -- -- 
          Moderate Risk 0.129 1.137 (1.010, 1.281)* 0.03 
          High Risk 0.210 1.234 (1.095, 1.391)* 0.00 
     HDL Levels    
          Preventive (reference) -- -- -- 
          Normal -0.156 0.856 (0.761, 0.962)* 0.00 
          High Risk -0.051 0.950 (0.824, 1.097) 0.48 
     Age    
          18 to 40 years old (reference) -- -- -- 
          41 to 55 years old 0.632 1.881 (1.688, 2.097)* 0.00 
               
Older than 55-years-old 1.088 2.969 (2.628, 3.354)* 0.00 
     Total Blood Cholesterol Levels    
          Normal (reference) -- -- -- 
          Moderate Risk 0.140 1.151 (1.041, 1.272) 0.00 
          High Risk 0.235 1.264 (1.096, 1.459) 0.00 
     BMI    
          Normal (reference) -- -- -- 
          Underweight 0.150 0.161 (0.726, 1.858) 0.53 
          Overweight 0.444 1.560 (1.382, 1.760)* 0.00 
          Obese 0.760 2.138 (1.886, 2.423)* 0.00 
χ
2
 = 4.654*, p = 0.03, Cox & Snell’s R
2
 = 0.05 
* Significant at p < 0.05, 
a 
H/O – history of 
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CHAPTER IV 
PREDICTORS OF UNCONTROLLED HYPERTENSION INTWO COUNTIES 
OF THE STROKE BELT 
 
 
Introduction 
Hypertension (HT), defined as having a systolic blood pressure (SBP) level of 
140 mmHg and/or a diastolic BP (DBP) level of 90 mmHg and over, is a major risk 
factor for cardiovascular diseases (CVD) and stroke.
1
 HT was either the primary or 
contributing cause of death for over 300,000 Americans in 2006.
2, 3
 The National High 
Blood Pressure Education Program (NHBPEP) and the Joint National Committee on 
Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) have 
stipulated guidelines for treatment and control of HT. These guidelines serve as a 
platform for all healthcare providers, public health researchers and practitioners to focus 
on key elements of lifestyle modification and pharmacological aspects of HT 
management.
4, 5
  
Due to ongoing efforts of NHBPEP, the number of individuals in the U.S. who 
are on medication and thus controlling their BP levels has increased dramatically during 
the last two decades. According to the National Health and Nutrition Examination Survey 
(NHANES) report for 1991-1994, of those who were hypertensive and taking BP 
lowering medications, 53.6% and 27.4% were controlling SBP levels to less than 140 
mmHg and DBP levels to less than 90 mmHg,  respectively, compared to 31% and 10% 
respectively in 1976-1980.
2
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In spite of continued efforts to treat and control HT at a national level, success has 
been limited.
6
 There are concerns that the trends reported in the NHANES report may be 
subsiding.
5
 According to the Framingham Heart Study (FHS) by the National Heart Lung 
Blood Institute (NHLBI), only 38% of men aged 80 years and older and 23% of women 
aged 80 years and older had BP under control, as per the guidelines set forth by NHBPEP 
and JNC 7. These trends were similar for both men (38%) and women (38%) aged 60 
years or less.
7
 Another study investigated the NHANES data from 2003-2004, to explore 
inadequate control of HT among adults aged 18 years and older with cardiovascular 
disease (CVD) co-morbidities such as coronary artery disease (CAD), heart failure (HF), 
diabetes mellitus (DM), stroke, etc. in the United States (U.S.). The authors reported that 
75% of their study population who were hypertensive and taking BP lowering 
medications; approximately 30-50% of those individuals did not have their BP under 
control, i.e., SBP and DBP less than 140 and 90 mmHg respectively. Moreover, isolated 
systolic HT was the most prevalent uncontrolled type of HT among individuals with a 
mean systolic BP of 20 mmHg higher than normal.
8 
 
Systolic HT prevalence rates increase with age and, SBP level is the main risk 
factor for cardiovascular diseases after 50 years of age.
9
 The JNC 7 report suggests that 
there is a greater need to focus on isolated SBP as a major risk factor for CVDs and 
strokes. Studies have shown that SBP levels continue to rise throughout life, whereas 
DBP levels start to taper off after 50 years of age.
10, 11
 Franklin et al., explored the 
hemodynamic patterns of age-related changes in BP and found that age-related changes 
leading to increasing SBP levels and decreasing DBP levels after 50 years of age are 
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mainly attributed to large artery stiffness. They also suggest that the dominant 
hemodynamic factor in normotensive and hypertensive individuals is large artery 
stiffness compared to vascular resistance. If HT is left untreated or uncontrolled, large 
artery stiffness would worsen, thereby perpetuating a vicious cycle of elevated BP levels 
and arterial stiffness.
11
 Furthermore, guidelines to maintain SBP levels below 140 mmHg 
among older individuals continue to remain controversial.
9, 12 
Non-adherence to BP lowering medications and recommendations serve as 
another contributing factor to uncontrolled HT, especially among minority populations. 
According to The Cohort Study of Medication Adherence in Older Adults (CoSMO), a 
prospective study among older adults with essential hypertension, the authors found that 
black participants not only had a significantly higher prevalence of uncontrolled 
hypertension, but also had a lower level of adherence to BP lowering medications 
compared to whites. This study reported a strong association between self-reported non-
adherence and uncontrolled BP levels determined by clinical readings.
13
 Vawter et al. 
conducted a study to assess barriers to antihypertensive medication adherence among 
adults in the U.S. The authors found that almost one third of the participants reported 
several barriers to antihypertensive therapy. "Not remembering'' was the most common 
reason reported (32.4%), followed by high cost (22.6%), having no insurance (22.4%), 
side effects (12.5%) and other reasons.
14
  
Although there have been studies that have investigated adherence issues of 
antihypertensive therapy, very little is known about the relationship between 
demographics and adherence issues particularly among older populations.
13, 15 
In order to 
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better develop and implement interventions that are population-specific, culturally 
competent, and community-based, it is important to understand and assess factors 
associated with uncontrolled HT. This study aims to assess demographic, self-reported 
and clinical predictors of uncontrolled HT among individuals taking BP-lowering 
medications.  
Methods 
CITIES Project 
The CITIES project of North Carolina (NC) was supported for three years by the 
U.S. DHHS, Office of Minority Health (OMH), and awarded to the Forsyth Medical 
Center (FMC) Foundation in formal partnership with the Moses Cone Health System 
(MCHS), the University of North Carolina at Greensboro (UNCG) and the North 
Carolina Agriculture & Technical State University (NC A&T). This initiative was 
implemented in two North Carolina counties, Guilford and Forsyth, and targeted minority 
populations, low-income individuals, those who spoke English as a second language and 
persons who lived in rural areas. The main components of the CITIES project were to: (a) 
screen individuals for stroke risk factors; (b) make recommendations and referrals as 
appropriate for identified risk factors; and (c) provide health education and health 
promotion activities for stroke risk factors.
16 
Settings and Procedures 
Each medical center used a mobile unit and registered nurses (RN) to screen 
individuals with preset appointments at designated sites in both counties, such as 
churches, factories, health fairs, etc. and at sites with unscheduled appointments within 
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the two respective counties. Participation was voluntary and each participant was 
included if they were 18 years or older and signed the consent form. The RNs used a 
standard questionnaire that gathered data on self-reported questions, stroke risk profile, 
and clinical and biomedical measurements. A total of 19,621 individuals were screened 
for stroke risk factors in the CITIES project. A convenience sub-sample of 2,663 
individuals who were taking BP-lowering medications was chosen for this study. The 
participants were asked to self-report their HT medication status by answering the 
following question: “Do/Did you take any medications to control your blood pressure?” 
Inclusion in the sample was based on a ‘yes’ response to the question about BP-lowering 
medications.  
The RNs measured the blood pressure of each participant using an electronic 
machine – DYNAMAP, which was wet-tested and calibrated every week. A minimum of 
two measurements were taken in the seated position with one of the arms outstretched 
and the lowest BP reading was recorded. If the first reading was high, i.e., high systolic 
and/or diastolic BP, then BP was measured again after two minutes in the same arm. If 
the readings on the machine were found to be high on both occasions, then the registered 
nurses would manually measure the blood pressure twice in the other arm, using a 
calibrated sphygmomanometer, and then record the lowest readings. All participants who 
had a BP measurement of 160 mmHg for systolic and/or 100 mmHg for diastolic or 
higher were referred to an E.R. promptly to get their BP checked again. The RNs also 
collected demographic information from all participants. 
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Other self-reported information included overweight status, smoking, exercise 
status, presence or absence of diabetes mellitus, non-adherence with BP lowering 
medications and use of lipid-lowering medications.
16
 All self-reported information was 
collected prior to collection of blood samples and recording of clinical and biomedical 
measurements. Clinical and biomedical measurements included blood LDL, HDL, total 
cholesterol, triglycerides and glucose levels. BMI was calculated based on self-reported 
height and measured weight. The project was approved by the respective Institutional 
Review Boards for each institution. 
Statistical Analyses 
All cut-points for uncontrolled HT, SBP and DBP levels were based on the JNC 7 
definition and classification of HT.
5
 MS Access
©
 was used to input data, which was 
analyzed using PASW statistics software, version 18.
17, 18
 The final sample excluded 
individuals who were not taking BP lowering medications in order to avoid confounding 
results. The participants’ demographic characteristics, self-reported information and 
clinical measurements were described using frequencies and percentages. Age was 
dichotomized to test the associations between uncontrolled levels of BP and individuals 
older than 55 years. Most studies have cited ages 50 to 65 years of age as a cut-off to 
discern age-related differences in control of HT. Furthermore, 55 years of age was used 
as a cut-off in our analysis to achieve proportionate sizes in each age category. Bivariate 
associations were calculated using cross-tabulations to compare self-reported information 
(yes and no) from the questionnaire with uncontrolled levels of SBP and DBP (yes and 
no) based on clinical measurements.  
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Odds ratios and confidence intervals (CI) at 95% were calculated using standard 
procedures to assess determinants of uncontrolled SBP and DBP. Uncontrolled SBP and 
DBP, the outcome variables were modeled as a function of independent variables 
including, demographic characteristics, self-reported information and clinical 
measurements reported. Binary logistic regression and forward likelihood ratio method 
were used to evaluate statistically significant predictors of BP control. Separate 
regression analyses were conducted on a sub-sample of individuals who self-reported to 
be compliant with BP lowering medications. The Hosmer and Lemeshow Goodness-of-
Fit test was conducted to assess the fit of the final model and its estimates. The statistical 
significance for all analyses was based on the conventional alpha level of significance of 
0.05. 
Results 
A total of 2,663 participants who reported that they did or were taking BP-
lowering medications were included in the final analysis. A description of demographic 
characteristics is provided in Table 1. Almost two-thirds of the participants were females. 
A majority of the participants were African Americans (52.2%) and 42% were whites. 
Almost 50% of the participants had a high school level education or less. About one third 
of the participants had LDL and HDL levels in the high risk categories (see Table 2). 
Approximately 40% of the participants had moderate to high total blood cholesterol and 
triglyceride levels. Less than 10% of the sample size had blood glucose levels higher than 
150 mg/dl (normal non-fasting levels). Two thirds of the participants were either 
overweight or obese based on their BMI levels. The mean SBP and DBP levels were 
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138.39 mmHg (SD = 19.58) and 81.67 mmHg (SD = 10.65) respectively. The prevalence 
of uncontrolled systolic HT and diastolic HT in our population sample was 43.5 and 22.8 
respectively.  
A description of self-reported information is presented in Table 3. Less than 15% 
of the participants reported a personal history and one third reported a family history of 
CVD. Slightly over half (52.6%) of the participants reported a lack of exercise in their 
daily lives, while more than half of the participants reported that they were overweight. 
Approximately one fifth of the participants reported having diabetes. Less than 10% of 
the population sample reported non-adherence with their BP-lowering medications, citing 
forgetfulness, side-effects and high cost as potential reasons for non-adherence.  
Bivariate analyses using unadjusted odds ratios were explored to assess 
differences and associations of respondent characteristics with uncontrolled HT (see 
Table 4). African Americans were more likely to have uncontrolled isolated SBP and 
DBP compared to whites. Participants who were older than 55 years of age were about 
1.5 times as likely to have uncontrolled SBP levels compared to individuals 55 years of 
age and younger. Participants with less than high school education were more likely to 
have uncontrolled SBP than those who had a high school level education or more. 
Participants with no personal history of atrial fibrillation or CVD were more likely to 
have uncontrolled DBP compared to those who had a history of either of those 
conditions. Smokers were almost twice as likely to have uncontrolled DBP compared to 
non-smokers.  
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Non-adherence with BP-lowering medication recommendations were positively 
associated with uncontrolled levels of BP. Participants who report non-adherence were 
more than twice as likely to have uncontrolled isolated SBP and DBP compared to 
compliant participants. Individuals who were in the obese category based on BMI levels 
were 1.4 times as likely to have uncontrolled DBP levels compared to normal weight 
individuals. Similarly, participants with moderate to high risk for increased blood glucose 
levels were also 1.4 times as likely to have uncontrolled SBP levels as compared to those 
individuals with normal blood glucose levels.  
A multivariate logistic regression using a stepwise forward likelihood ratio 
indicated that, non-adherence to BP-lowering medications (OR = 2.450, p = 0.00), age 
(OR = 1.666, p = 0.00), race (OR = 1.558, p = 0.00), blood triglyceride levels (OR = 
1.490, p = 0.00), and, blood glucose levels (OR = 2.107, p =0.01), and were significant 
predictors of uncontrolled SBP levels (χ
2
 = 6.735, p = 0.03, Cox & Snell’s R
2
 = 0.04) (see 
Table 5). African Americans, individuals older than 55 years of age, self-reported to be 
non-adherent with BP-lowering medications, with high risk levels of blood glucose and a 
moderate risk for blood triglyceride levels were more likely to have uncontrolled SBP 
levels compared to the reference groups. These results were similar to the bivariate 
analysis discussed above. The Hosmer and Lemeshow Goodness-of-Fit test for the final 
model was non-significant (χ
2
 = 9.919, p = 0.19) indicating that the logistic model and its 
estimates are a good fit. Cross-tabulations were conducted to further explore level of BP 
control between select groups of individuals that were found to be significant predictors. 
Approximately 60% of the participants that were African Americans aged 18-55 years 
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old were controlling their SBP levels below the recommended level of 140 mmHg (n = 
717). A multivariate logistic regression using a stepwise forward likelihood ratio also 
indicated that, age (OR = 0.461, p = 0.00), race (OR = 2.173, p = 0.00), gender (OR = 
1.953, p = 0.00), non-adherence with BP-lowering medications (OR = 2.342, p = 0.00), 
personal history of atrial fibrillation (OR = 0.477, p = 0.03) and, smoking (OR = 1.376, p 
= 0.03), and were significant predictors of uncontrolled DBP levels (χ
2
 = 4.528, p = 0.03, 
Cox & Snell’s R
2
 = 0.09). Males, African Americans, individuals 55 years old or 
younger, smokers, with no personal history of atrial fibrillation were more likely to have 
uncontrolled DBP levels compared to their respective reference groups. These results 
were also similar to the bivariate analysis discussed above. The Hosmer and Lemeshow 
Goodness-of-Fit test for the final model was non-significant (χ = 4.261, p = 0.74) 
indicating that the logistic model and its estimates are a good fit. Almost two thirds 
(66.4%) of younger African American females were controlling their diastolic blood 
pressure levels below the recommended level of 90 mmHg. (n = 521). 
In order to evaluate predictors of uncontrolled SBP and DBP among individuals 
who were taking BP-lowering medications and self-reported to be compliant with the 
medication recommendations, multivariate logistic regression using a stepwise forward 
likelihood ratio using this sub-sample (χ
2
 = 6.244, p = 0.04, Cox & Snell’s R
2
 = 0.03). 
Age (OR = 1.682, p = 0.00), race (OR = 1.561, p = 0.00), and blood triglyceride levels 
(OR = 1.519, p = 0.00) were significant predictors of uncontrolled SBP levels (see Table 
6). African Americans, individuals older than 55 years of age and those with high risk 
levels of blood triglycerides were more likely to have uncontrolled SBP levels compared 
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to the reference groups. The Hosmer and Lemeshow Goodness-of-Fit test for the final 
model was non-significant (χ = 6.055, p = 0.41) indicating that the logistic model and its 
estimates are a good fit. Age (OR = 0.508, p = 0.00), race (OR = 2.172, p = 0.00), gender 
(OR = 1.864, p = 0.00), and personal history of atrial fibrillation (OR = 0.374, p = 0.01) 
were significant predictors of uncontrolled DBP levels (χ
2
 = 7.237, p = 0.00, Cox & 
Snell’s R
2
 = 0.06). Males, African Americans, individuals younger than 55 years of age, 
with no personal history of atrial fibrillation were more likely to have uncontrolled DBP 
levels compared to the reference groups. The Hosmer and Lemeshow Goodness-of-Fit 
test for the final model was non-significant (χ = 1.096, p = 0.99) indicating that the 
logistic model and its estimates are a good fit. While the pseudo-R
2
 in all our models 
were low, the Hosmer and Lemeshow tests were non-significant indicative of an adequate 
fit of all the final models with the available data. 
Discussion 
The mean SBP and DBP levels of our sample fell in the classification for 
prehypertension for high blood pressure (JNC7). The control rates for HT in our cross-
sectional population were slightly higher than the national rates and for those reported in 
other studies.
6, 19, 20, 21
 Among those who had comorbidities associated with HT, 
approximately 25% of the population sample self-reported as having diabetes mellitus. In 
addition, two thirds of our population was either overweight or obese based on their BMI 
levels. Approximately 40% of the participants also had high blood cholesterol and 
triglyceride levels. The presence of comorbidities such as diabetes mellitus and high risk 
BMI levels further compounds achievement of BP control.
20
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Despite continued efforts to reduce disparities in management and control of HT, 
our results indicate that African Americans are at a greater risk for both uncontrolled 
systolic and diastolic HT. Fongwa et al conducted a qualitative study to evaluate and 
assess barriers to and facilitators of medication adherence among hypertensive African 
American women aged 35 years and older.
22
 They conducted five focus groups and found 
that barriers to effective control of HBP were mainly associated with side effects, cost of 
medications, personal stress, stress from the social system, SES and lack of physical 
activity among other barriers. The authors also found that facilitators to effective control 
included, but were not limited to, positive and proactive behavioral and lifestyle changes.  
A similar study conducted by Ogedegbe et al found that among hypertensive 
African American patients in two primary care centers, patient-specific barriers were 
most commonly reported.
23
 These barriers included forgetfulness, beliefs that 
medications are undesirable and cause impotency, and attitudes such as not taking 
responsibility for one’s health. Other barriers included medication-specific issues, such as 
side-effects and cost, disease specific issues, such as absence of symptoms versus having 
symptoms, and logistic-specific issues, such as access to health care and medications. 
The findings of these studies are consistent with the results of our analyses and other 
studies conducted among African American populations.
24, 25, 26, 27 
Hyman et al., found that individuals who were at least 65 years old were 
associated with the highest relative risk and attributable risk of uncontrolled HT.
9
 Our 
findings suggest that individuals who are older than 55-years-of-age were at the greatest 
risk for failure to control their SBP levels whereas younger individuals were more likely 
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to suffer from uncontrolled DBP levels. Similar findings have been reported in other 
studies that investigated the role of SBP and DBP levels in coronary heart disease risk 
change with aging.
28, 29
 Other studies have also shown that lack of control of SBP as a 
result of inadequate management are largely responsible for poor overall control of HBP 
levels in the U.S. population.
9, 30, 31, 32
 Growing evidence supports the notion that 
physicians should focus on controlling elevated SBP particularly in older individuals.
33, 34
 
Studies that have surveyed physicians have shown that three fourths of them did not 
initiate appropriate treatment in older individuals with SBP of 140 mmHg or more. 
Moreover most providers did not pursue NHBPEP stipulated goals of controlling SBP to 
levels less than 140 mmHg.
35, 36
 JNC 7 reports that most physicians are trained to focus 
on DBP levels and treat it accordingly, as opposed to SBP levels, which have a more dire 
effect on individuals affected by hypertension after the age of 50 years.  
Based on our findings, we support the recommendation purported by NHBPEP to 
focus on controlling SBP as a means to effectively manage HT particularly in older 
adults. It is also recommended for practitioners to design interventions to better manage 
HT-associated risk factors such as high cholesterol, high BMI and diabetes, and target 
males, African-Americans and younger individuals to adequately control their DBP 
levels.     
Conclusion 
In conclusion, few studies have comprehensively evaluated the information 
regarding predictors of uncontrolled BP levels, such as demographic characteristics, self-
reported co-morbidities and clinical correlates of hypertension. Age, race and medication 
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non-adherence were significant predictors of both isolated uncontrolled SBP and DBP 
levels. Similar results were found for individuals who were adherent with BP-lowering 
medications. Although the efforts of NHBPEP have shown improvements in awareness, 
treatment and control of HBP, one third of the U.S. population still suffers from 
uncontrolled hypertension. African Americans are more prone to suffer from 
uncontrolled hypertension as compared to other racial/ethnic groups.  
The goal of Healthy People 2010 was to decrease the prevalence of hypertension 
among African American from 40% to 16%. Several studies have shown that 
uncontrolled BP levels are mainly attributable to systolic pressure. JNC 7 has emphasized 
the need for practitioners and public health professionals to focus on controlling SBP 
levels among hypertensive populations. Further research and clinical trials may be 
warranted to support this plan of action. Forty three percent of our sample had 
uncontrolled systolic HT. Future drug trials could elucidate the differential effects of BP-
lowering medications on controlling isolated SBP or DBP levels. There is also a growing 
need for healthcare providers to better manage and target systolic HT to achieve better 
overall control of HT particularly in the older populations. Finally, public health research 
and interventions for HT and other correlated CVD risk factors should be designed to 
reduce gender and racial disparities.     
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Tables 
 
Table 1: Demographic Characteristics of Respondents
* 
in CITIES 
Project, NC 2004-2007 
Personal Characteristics                Total 
N (2,663) % 
Gender   
Female 1,840 69.3 
    Male 816 30.7 
Race   
    Caucasian 1,118 42.0 
    African American 1,391 52.2 
    Hispanic 14 0.5 
    Asian/Pacific Islander 44 1.7 
    Other 52 2.0 
Age   
     18 to 55 years old 1,238 46.7 
     < 55 years old 1,412 53.3 
Income    
     < $35,000 1,782 70.7 
     > $35,000 738 29.3 
Education   
     Less than High School 193 7.4 
     High School or GED 1,008 38.8 
     More than High School  1,396 53.8 
Ethnicity    
     Hispanic/Latino  44 1.7 
     Non-Hispanic/Latino 2575 98.3 
*
 Totals do not sum to the sample size due to missing data. 
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Table 2: Clinical Characteristics of Respondents
*
 in CITIES Project, NC 2004-2007 
Clinical Characteristics                    Total 
N (2,663) % 
LDL   
   Optimum (< 99 mg/dl)    641 30.9 
   Near Optimum/Above Optimum (100-129 mg/dl) 833 40.1 
   Borderline High Risk (130-159 mg/dl)             434 20.9 
   High Risk (160-189 mg/dl) 129 6.3 
   Very High Risk (> 190 mg/dl) 38 1.8 
HDL   
   Preventive (> 60 mg/dl)  602 23.0 
   Normal (40-59 mg/dl) 1,244 47.6 
   High Risk (< 40 mg/dl) 770 29.4 
Total Cholesterol   
   Normal (< 199 mg/dl) 1,649 62.7 
   Moderate Risk (200-239 mg/dl) 741 28.2 
   High Risk (> 240 mg/dl) 240 9.1 
Triglyceride   
   Optimum (< 149 mg/dl) 1,385 52.7 
   Borderline High Risk (150-199 mg/dl) 479 18.2 
   High Risk (> 200 mg/dl) 762 29.0 
Blood Glucose   
   Normal (50-149) 2,359 89.9 
   Moderate Risk (150-199 mg/dl) 174 6.6 
   High Risk (> 200 mg/dl) 92 3.5 
BMI   
   Underweight (< 18.5) 24 0.9 
   Normal (18.5-24.9999) 436 16.5 
   Overweight (25-29.9999) 885 33.5 
   Obese (>30) 1,295 49.1 
Systolic BP   
   Controlled (normal) (< 119 mmHg) 1,485 56.5 
   Uncontrolled (> 119 mmHg) 1,141 43.5 
Diastolic BP   
   Controlled (normal) (< 79 mmHg) 2,022 77.2 
   Uncontrolled (> 79 mmHg) 598 22.8 
Combined Systolic and Diastolic BP   
   Controlled (normal)  2,121 81.5 
   Uncontrolled  480 18.5 
   
*
Totals do not sum to the sample size due to missing data. 
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Table 3: Self-Reported Characteristics of Respondents
*
 in CITIES 
Project, NC 2004-2007 
Self-Reported Characteristics                Total 
N (2,663) % 
Personal History of CVD   
 No 2,281 85.7 
     Yes 382 14.3 
History of Atrial Fibrillation   
     No 2,548 95.7 
     Yes 115 4.3 
Family History of CVD   
     No 1,774 66.6 
     Yes 889 33.4 
Smoking    
     No 2,256 84.7 
     Yes 407 15.3 
Overweight Status   
     No 941 35.3 
     Yes 1,722 64.7 
Lack of Exercise Status   
     No  1,263 47.4 
     Yes 1,400 52.6 
High Blood Cholesterol Status   
     No 1,497 56.2 
     Yes 1,166 43.8 
Diabetes Status   
     No 2,102 78.9 
     Yes 561 21.1 
Stress Status   
     No 2,044 76.8 
     Yes 619 23.2 
Non-compliance with BP-
Lowering Medications 
  
    No 2,453 92.1 
    Yes 210 7.9 
         Due to High Costs 29 14.4 
         Due to Side-effects 45 22.4 
         Due to Forgetfulness 56 27.9 
         Due to Other Reasons 71 35.3 
*
Totals do not sum to sample size due to missing data 
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Table 4:  Bivariate Analysis – Determinants of Uncontrolled SBP and DBP by Demographic, 
Self-Reported and Clinical Characteristics in CITIES Project, NC 2004-2007 
Participant Characteristics SBP 
Odds Ratio (95% CI) 
DBP 
Odds Ratio (95% CI) 
     Gender    
          Female (reference) -- -- 
       Male 0.975 (0.825, 1.153) 1.554* (1.283, 1.882) 
     Race   
       Caucasian (reference) -- -- 
               
African Americans 1.414* (1.204, 1.661) 2.350* (1.917, 2.881) 
     Age   
       18-55-years-old (reference) -- -- 
               
Older than 55-years-old 1.522* (1.302, 1.779) 0.428* (0.355, 0.517) 
  Income   
       > $35,000 (reference) -- -- 
       < $35,000 1.468* (1.229, 1.753) 1.039 (0.846, 1.277) 
  Education   
       Less than High School (reference) -- -- 
       High School or More 0.819* (0.701, 0.958) 1.093 (0.908, 1.316) 
  Personal History of CVD   
          No (reference) -- -- 
          Yes 1.057 (0.848, 1.318) 0.598* (0.445, 0.802) 
  History of Atrial Fibrillation   
          No (reference) -- -- 
          Yes 1.118 (0.768, 1.627) 0.505* (0.291, 0.877) 
  Family History of CVD   
          No (reference) -- -- 
          Yes 0.998 (0.847, 1.175) 0.895 (0.736, 1.088) 
  Smoking Status   
          No (reference) -- -- 
          Yes 1.186 (0.958, 1.467) 1.735* (1.373, 2.192) 
  Overweight Status   
          No (reference) -- -- 
          Yes 1.039 (0.884, 1.221) 1.168 (0.962, 1.417) 
  Lack of Exercise Status   
          No (reference) -- -- 
          Yes 1.044 (0.895, 1.219) 1.191 (0.991, 1.431) 
  Non-adherence with BP-Lowering       
  Medications 
  
          No (reference) -- -- 
          Yes 2.431* (1.806, 3.271) 2.398* (1.783, 3.226) 
  High Blood Cholesterol Status   
          No (reference) -- -- 
          Yes 0.905 (0.775, 1.058) 0.592* (0.489, 0.716) 
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  Diabetes Status   
          No (reference) -- -- 
          Yes 1.268* (1.050, 1.531) 0.649* (0.509, 0.827) 
  Stress Status   
          No (reference) -- -- 
          Yes 0.930 (0.774, 1.117) 1.094 (0.884, 1.354) 
  Total Blood Cholesterol   
          Normal (reference)   
          Moderate to High Risk 1.066 (0.908, 1.251) 1.177 (0.976, 1.419) 
  LDL   
          Normal (reference) -- -- 
          High Risk 1.007 (0.827, 1.225) 1.240 (0.992, 1.550) 
  HDL   
          Normal (reference) --  -- 
          High Risk 0.886 (0.747, 1.052) 0.933 (0.761, 1.143) 
  Triglycerides   
          Normal (reference) -- -- 
          Moderate Risk 1.266 (1.027, 1.561)* 1.111 (0.871, 1.417) 
          High Risk 1.071 (0.895, 1.281) 0.904 (0.729, 1.122) 
  BMI   
          Normal (reference) -- -- 
          Underweight 1.186 (0.521, 2.698) 1.726 (0.693, 4.298) 
          Overweight 0.769* (0.610, 0.970) 1.130 (0.847, 1.509) 
          Obese 0.992 (0.798, 1.234) 1.402* (1.069, 1.838) 
  Blood Glucose   
          Normal (reference) -- -- 
          Moderate to High Risk 1.412 * (1.093, 1.823) 0.975 (0.718, 1.323) 
* Significant at p < 0.05 
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Table 5: Logistic Regression – Predictors of Uncontrolled SBP and DBP by Demographic, Self-
Reported and Clinical Characteristics in CITIES Project, NC 2004-2007 
Participant Characteristics β SBP Odds Ratio (95% CI) p 
     Adherence to BP Medications    
          Yes (Reference) -- -- -- 
          No 0.896 2.450 (1.738, 3454)* 0.00 
     Age    
       18-55-years-old (reference) -- -- -- 
               
Older than 55-years-old 0.510 1.666 (1.376, 2.017)* 0.00 
     Race    
       Caucasian (reference) -- -- -- 
               
African Americans 0.443 1.558 (1.272, 1.908)* 0.00 
          Hispanics/Latinos 0.671 1.957 (0.508, 7.541) 0.32 
          Asians/Pacific Islander 0.487 1.627 (0.779, 3.396)  0.19 
          Others 0.452 1.572 (0.796, 3.105) 0.19 
  Triglycerides    
          Normal (reference) -- -- -- 
          Moderate Risk 0.399 1.490 (1.164, 1.907)* 0.00 
          High Risk 0.217 1.242 (0.982, 1.571) 0.07 
  Blood Glucose    
          Normal (reference) -- -- -- 
          Moderate Risk -0.069 0.933 (0.610, 1.427) 0.74 
          High Risk 0.745 2.107 (1.171, 3.791)* 0.01 
Participant Characteristics β DBP Odds Ratio (95% CI) p 
     Age    
       18-55-years-old (reference) -- -- -- 
               
Older than 55-years-old -0.775 0.461 (0.367, 0.579)* 0.00 
     Race    
       Caucasian (reference) -- -- -- 
               
African Americans 0.776 2.173 (1.708, 2.765)* 0.00 
          Hispanics/Latinos 0.919 2.507 (0.588, 10.682) 0.21 
          Asians/Pacific Islander 1.050 2.857 (1.309, 6.233)*  0.00 
          Others 0.290 1.337 (0.580, 3.082) 0.49 
     Gender    
          Female (reference) --  -- 
          Male 0.669 1.953 (1.543, 2.472)* 0.00 
     Adherence to BP Medications    
          Yes (Reference) --  -- 
          No 0.808 2.242 (1.580, 3.183)* 0.00 
     H/O
a
 Atrial Fibrillation    
          No (Reference) --   
          Yes -0.741 0.477 (0.242, 0.938)* 0.03 
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     Smoking Status    
          Non-Smoker (Reference) --   
          Smoker 0.320 1.376 (1.029, 1.842)* 0.03 
* Significant at p < 0.05 
a
 H/O – History Of 
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Table 6: Logistic Regression – Predictors of Uncontrolled SBP and DBP by Demographic, Self-
Reported and Clinical Characteristics Among Compliant Participants in CITIES Project, NC 2004-
2007 
Participant Characteristics β SBP Odds Ratio (95% CI) p 
     Age    
       18-55-years-old (reference) -- -- -- 
               
Older than 55-years-old 0.520 1.682 (1.380, 2.050)* 0.00 
     Race    
       Caucasian (reference) -- -- -- 
               
African Americans 0.446 1.561 (1.267, 1.924)* 0.00 
          Hispanics/Latinos 1.020 2.773 (0.643, 11.968) 0.17 
          Asians/Pacific Islander 0.534 1.706 (0.822, 3.542)  0.15 
          Others 0.270 1.309 (0.636, 2.697) 0.46 
     Blood Triglyceride Levels    
       Normal (reference) -- -- -- 
               
Moderate Risk 0.418 1.519 (1.179, 1.958)* 0.00 
          High Risk 0.186 1.205 (0.943, 1.539) 0.13 
Participant Characteristics β DBP Odds Ratio (95% CI) p 
     Age    
       18-55-years-old (reference) -- -- -- 
               
Older than 55-years-old -0.677 0.508 (0.401, 0.644)* 0.00 
     Race    
       Caucasian (reference) -- -- -- 
               
African Americans 0.775 2.172 (1.686, 2.797)* 0.00 
          Hispanics/Latinos 1.172 3.228 (0.735, 14.165) 0.12 
          Asians/Pacific Islander 1.056 2.876 (1.327, 6.231)*  0.00 
          Others -0.063 0.939 (0.350, 2.516) 0.90 
     Gender    
          Female (reference) -- -- -- 
          Male 0.623 1.864 (1.456, 2.385)* 0.00 
     H/O
a
 Atrial Fibrillation    
          No (Reference) -- -- -- 
          Yes -0.983 0.374 (0.168, 0.835)* 0.01 
* Significant at p < 0.05 
a
 H/O – History Of 
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CHAPTER V 
 
EPILOGUE 
 
 
Findings from study 1 suggest that individuals who had a possible diagnosis of 
hypertension based on their clinical measures were likely to report as not having 
hypertension. The sensitivity of self-reported information about one’s hypertension status 
was low. The overall agreement between one’s self-reported information and actual 
clinical measures, based on kappa scores were only fair. Therefore, self-reported 
information for hypertension should be used only with great care as a screening tool in 
large, population-based studies. Almost 25% of the participants in our sample had high 
blood pressure based on their clinical measures. Several national studies have reported 
similar findings.  
Despite continued efforts to raise awareness and educate the general population 
about hypertension; approximately one third of the U.S. population is unaware of their 
hypertension status. Therefore it is imperative to plan population-based interventions that 
target individuals most in need. This study identified several participant characteristics 
that were significantly associated with negative congruency i.e. decreased awareness of 
one’s hypertension status. These characteristics included gender (males), race (African-
Americans), age (those aged 55 years and older), and those who were in a high risk 
category for several hypertension and CVD-related correlates (HDL, triglycerides etc.).  
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Hence future interventions should employ strategies that increase availability and 
encourage participation of individuals in preventative care services, including getting an 
annual physical. The authors of this study collected information on possible diagnosis of 
hypertension; thus future research could also focus on evaluating the accuracy of 
screening data as an indicator of actual diagnosis of hypertension. 
Based on the findings of study 2, almost half of the participants who were taking 
blood pressure lowering medications had uncontrolled systolic hypertension. Almost 25% 
of the participants were not controlling their diastolic blood pressure levels below the 
recommended JNC 7 levels. The mean systolic and diastolic blood pressure fell in the 
JNC 7 classification for prehypertension. The findings of this study suggest that racial 
disparities continue to persist when it comes to controlling blood pressure levels. African 
Americans were at the greatest risk to suffer from uncontrolled systolic and diastolic 
hypertension compared to whites.  
This study also found that participants older than 55 years of age were more likely 
to have isolated uncontrolled systolic hypertension compared to younger participants. 
The National High Blood Pressure Education Program has recommended that physicians 
focus on better management of systolic blood pressure as a means to achieve optimum 
control of overall hypertension rates in the population. Several studies have shown that 
physicians do not adequately address management of systolic blood pressure particularly 
in older adults. Our results support NHBPEP’s call to enhance management of systolic 
blood pressure in older adults. Furthermore, future interventions could also target African 
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Americans males that are younger than 55 years of age to raise awareness, and control 
diastolic blood pressure levels. 
Strengths and Limitations 
Strengths:   
1. The strengths of this study include a large cross-sectional sample size and the 
availability of clinical measurements of BP and other associated correlates.  
2. Both studies were conducted in one of the stroke belt states, NC, which has higher 
stroke mortality rates when compared to the national average. To our knowledge, 
only a few studies have attempted to comprehensively evaluate the validity of self-
reported information and assess independent correlates of congruency of HT status in 
the stroke belt.  
3. These studies also used current definitions of HT as proposed by JNC 7 that served as 
‘gold standards’ to investigate the validity and predictors of positive congruency of 
HT status.  
4. For study 1, we excluded individuals who were taking BP-lowering medications in 
order to avoid confounding of results. All individuals who self-reported as taking BP-
lowering medications were automatically considered as self-reported hypertensive. It 
is important to note that, if these individuals were included in our final analysis, it 
would have led to an over-estimation of sensitivity of the screening test. 
Limitations: 
1. One limitation of both studies was that, participation in this study was voluntary as 
opposed to recruitment of a more generally representative segment of the population. 
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As a result, authors may have missed out on capturing information from non-
participants with a different set of knowledge about HT and its correlates.  
2. Another limitation of the studies was the use of only two readings of clinical BP in 
order to determine possible diagnosis of HT. The clinical measures of BP varies 
during the day and from day-to-day, therefore more stringent criteria have been 
suggested to diagnose HT in order to avoid over-estimation of clinical HT.  
3. Another possible limitation is ‘white-coat HT’, which reflects the stressful influence 
of nurses and the presence of clinical staff on one’s BP. 
4. Another limitation of study 2 was that the researchers did not collect information on 
the type of BP-lowering medications taken by the population sample. This would 
have allowed the authors to assess the effects of medications in controlling SBP 
and/or DBP levels and provide pharmacological linkage to management of HT.  
5. Less than 10% (n = 210) of participants indicated non-adherence to BP-lowering 
medications. Non-adherence to medications can be defined as not following clinically 
prescribed recommendations of regularly taking BP-lowering medications. We did 
not collect information if the participants were taking pills on alternate days or taking 
half the recommended dosage or were taking medications when he/she perceived 
symptoms related to high BP. It is quite possible that the number in our sample could 
have been higher if more accurate information was gathered concerning non-
adherence.   
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Future Work 
The results from these studies should be expanded to develop more culturally-
competent and comprehensive population-based interventions that increase the 
availability and encourage individuals to access preventive healthcare services including 
getting an annual physical. It is hypothesized that individuals who have regular access to 
healthcare services and get an annual physical will be more aware of their health status 
including risk factors associated with hypertension, CVD and stroke. Very few studies 
have assessed the associations between healthcare access and awareness of basic health 
information. Future research could be designed to focus on evaluating this association to 
better predict health outcomes for the populations. Several groups of individuals were 
either more likely to be unaware of their hypertension status or were less likely to control 
their blood pressure levels below the recommended JNC 7 levels. More research is 
needed to better explore compliance rates among African Americans and understand the 
differential effects of blood pressure lowering drugs. Healthcare professionals are 
encouraged to design intervention plans that include behavioral modifications and healthy 
lifestyle choices as a compliment to pharmaceutical management of high blood pressure. 
The findings of these studies could be used to develop targeted educational messages that 
focus on reducing racial and gender disparities and betterment of awareness, treatment 
and control of hypertension. I have been a part of this research project and team since 
2004. This research project and the mentorship provided by the CITIES staff has allowed 
me to gain more knowledge and a better understanding of population dynamics related to 
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hypertension and CVD. I have thoroughly enjoyed working on these two studies and look 
forward to enhancing my skills in this area at both personal and professional levels.  
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Title of Project: Secondary Analysis and Reporting of the CITIES Hypertension Data  
 
Principal Investigator: Daniel Bibeau  Department: Public Health Education 
*Students are not eligible to be principal investigators  
 
Have you taken CITI training?  X  Yes (If Yes, you do not need to attach a copy of your training 
certificate)     No (If No, then please attach proof of the completion of our accepted human 
subjects’ training) 
 
Campus Address: 437 HHP Building 
 
Email: dlbibeau@uncg.edu  Phone: 334-3240   Fax:       
 
RANK:  X  Faculty   Staff     Other (specify):       
 
Source of funding for your study (internal or external):        RAMSES Number:  
      
 
Co-Investigator: Mark Schulz and Robert Aronson  Department: Public 
Health Education 
 
Have you taken CITI training?  X Yes (If Yes, you do not need to attach a copy of your training 
certificate)     No (If No, then please attach proof of the completion of our accepted human 
subjects’ training) 
 
Campus Address: 437 HHP Building 
 
Email: mrschulz@uncg.edu, rearonso@uncg.edu  Phone: 334-5517, 256-0119   Fax: 
      
 
If this project represents student work please provide the student researcher rank: 
Undergraduate;    Masters; or   X Doctoral 
Student Researchers name: Gaurav Dave 
 
Have you taken CITI training?    Yes (If Yes, you do not need to attach a copy of your training 
certificate)   X  No (If No, then please attach proof of the completion of our accepted human 
subjects’ training) 
 
Email: gjdave@uncg.edu Phone: 334-5044        Fax:       
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Principal Investigator’s Statement of Responsibility 
As the principal investigator, my signature testifies that I have read and understood the University Policy 
and Procedures for the Use of Human Participants in Research. I assure the Committee that all procedures 
performed under this project will be conducted exactly as outlined in the Proposal Narrative and that any 
modification to this protocol will be submitted to the Committee in the form of a modification for its 
approval prior to implementation. 
 The proposed research does not include any of the items that are listed in Item B of the Exemption 
Overview 
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Signature of Co-Investigator (if applicable)     Date 
 
 
Student Researcher’s Statement of Responsibility 
As a student researcher, I accept responsibility for ensuring that this project complies with all obligations 
listed above for the Principal Investigator. 
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IRB <irbcorre@uncg.edu>  Mon, Sep 20, 2010 at 15:31  
To: bibeau@uncg.edu  
Cc: gjdave@uncg.edu, cifarrio@uncg.edu, irbcorre@uncg.edu  
To: Daniel Bibeau  
Public Health Education  
437G HHP Building 
 
From: UNCG IRB 
 
Date: 9/20/2010  
 
RE: Notice of IRB Exemption 
Exemption Category: 4.Existing data, public or deidentified  
Study #: 10-0322Study Title: Secondary Analysis and Reporting of the CITIES 
Hypertension Data 
 
This submission has been reviewed by the above IRB and was determined to be 
exempt from further review according to the regulatory category cited above under 45 
CFR 46.101(b).  
 
Study Description:  
 
The purpose of this project is to analyze the hypertension related data gathered as part 
of the CITIES stroke risk reduction project for the purpose of professional 
communication through presentations and publications.  
 
Investigator’s Responsibilities  
 
Please be aware that any changes to your protocol must be reviewed by the IRB prior 
to being implemented.  The IRB will maintain records for this study for three years 
from the date of the original determination of exempt status. 
 
CC:Gaurav Dave, Ctr Soc, Cmty Hlth Rsch And Eval, Chris Farrior, (ORED), Non-
IRB Review Contact, (ORC), Non-IRB Review Contact  
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1. Predictors of Congruency (Self-Reported versus Clinical Measures) 
After controlling for other covariates, a multivariate logistic regression using stepwise 
likelihood ratio model found that gender (p = 0.00), race (p = 0.00), age (p = 0.00), 
family history of CVD (p = 0.00), self-reported diabetes status (p = 0.02), total blood 
cholesterol (p = 0.00), HDL levels (p = 0.00), blood triglyceride levels (p = 0.00), and 
BMI (p = 0.00) were all statistically significant predictors of congruency. Cross-
tabulations and unadjusted odds ratios were conducted to further explore level of 
congruency between select groups of individuals that were found to be significant 
predictors. Males were 0.7 times less likely to be congruent with respect to the 
hypertension status compared to females (see Table 1). African-American females were 
0.8 times less likely to be congruent compared to white females. Furthermore, white 
females who were older than 55 years of age or 41-55 years old were less likely to be 
aware of their hypertension status compared to white females who were younger (18-40 
years old). 
 
Table 1:  Bivariate Analysis – Determinants of HT Awareness (Congruence) by Select 
Demographic Characteristics in CITIES Project, NC 2004-2007 
Participant Characteristics Odds Ratio 95% CI 
     Gender    
          Female (reference) -- -- 
       Male 0.732* 0.679, 0.789 
     Race   
       White Females (reference) -- -- 
               
African American Females 0.809* 0.733, 0.894 
     Age (White Females)   
       18-40 years old (reference) -- -- 
               
41 to 55 years old 0.395* 0.321, 0.486 
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> 55 years old 0.229* 0.185, 0.284 
* Significant at p < 0.05   
 
Approximately 4/5
th
 of the participants (88%) that were white females aged 18-40 years 
old were positively congruent i.e. more aware of their HT status (n = 3768).  
2. Predictors of uncontrolled systolic hypertension 
 
After controlling for other covariates, a multivariate logistic regression using a stepwise 
forward likelihood ratio indicated that, non-adherence to BP-lowering medications (OR = 
2.450, p = 0.00), age (OR = 1.666, p = 0.00), race (OR = 1.558, p = 0.00), blood 
triglyceride levels (OR = 1.490, p = 0.00), and, blood glucose levels (OR = 2.107, p 
=0.01), and were significant predictors of uncontrolled SBP levels (χ
2
 = 6.735, p = 0.03, 
Cox & Snell’s R
2
 = 0.04) (see Table 5). African Americans, individuals older than 55 
years of age, self-reported to be non-adherent with BP-lowering medications, with high 
risk levels of blood glucose and a moderate risk for blood triglyceride levels were more 
likely to have uncontrolled SBP levels compared to the reference groups. Cross-
tabulations and unadjusted odds ratios were conducted to further explore level of 
congruency between select groups of individuals that were found to be significant 
predictors (see table 2). African Americans were 1.4 times more likely to suffer from 
uncontrolled systolic hypertension (HT) compared to whites. African American 
individuals who were older than 55 years of age were 1.5 times more likely to have 
uncontrolled systolic blood pressure levels compared to younger African Americans. 
 
 
 
91 
 
Table 2:  Bivariate Analysis – Determinants of Uncontrolled Systolic Hypertension by Select 
Demographic Characteristics in CITIES Project, NC 2004-2007 
Participant Characteristics Odds Ratio 95% CI 
     Race   
       White (reference) -- -- 
               
African American  1.414* 1.204, 1.661 
     Age (African Americans)   
       18-55 years old (reference) -- -- 
               
> 55 years old 1.556* 1.255, 1.929 
* Significant at p < 0.05   
 
Approximately 60% of the participants that were African Americans aged 18-55 years 
old were controlling their systolic blood pressure levels below the recommended level of 
140 mmHg. (n = 717). 
3. Predictors of uncontrolled diastolic hypertension 
 
After controlling for other covariates, a multivariate logistic regression using a stepwise 
forward likelihood ratio also indicated that, age (OR = 0.461, p = 0.00), race (OR = 
2.173, p = 0.00), gender (OR = 1.953, p = 0.00), non-adherence with BP-lowering 
medications (OR = 2.342, p = 0.00), personal history of atrial fibrillation (OR = 0.477, p 
= 0.03) and, smoking (OR = 1.376, p = 0.03), and were significant predictors of 
uncontrolled DBP levels (χ
2
 = 4.528, p = 0.03, Cox & Snell’s R
2
 = 0.09). Males, African 
Americans, individuals 55 years old or younger, smokers, with no personal history of 
atrial fibrillation were more likely to have uncontrolled DBP levels compared to their 
respective reference groups. Cross-tabulations and unadjusted odds ratios were conducted 
to further explore level of congruency between select groups of individuals that were 
found to be significant predictors (see table 3). African Americans were 2.3 times more 
likely to suffer from uncontrolled diastolic hypertension compared to whites. African 
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Americans who were older than 55 years of age were 0.4 times less likely to have 
uncontrolled diastolic blood pressure compared to younger African Americans. 
Furthermore, African Americans males who were 55 years of age and younger were 1.5 
times more likely to have uncontrolled diastolic blood pressure levels compared to 
African American females in the same age group. 
Table 3:  Bivariate Analysis – Determinants of Uncontrolled Diastolic Hypertension by 
Select Demographic Characteristics in CITIES Project, NC 2004-2007 
Participant Characteristics Odds Ratio 95% CI 
     Race   
       White (reference) -- -- 
               
African American  2.350* 1.917, 2.881 
     Age (African Americans)   
       18-55 years old (reference) -- -- 
               
> 55 years old 0.473* 0.371, 0.603 
     Gender (African Americans 18-55 years)   
          Female (reference) -- -- 
       Male 1.511* 1.074, 2.126 
* Significant at p < 0.05   
 
Almost two thirds (66.4%) of younger African American females were controlling their 
diastolic blood pressure levels below the recommended level of 90 mmHg. (n = 521).  
 
DONE! 
 
 
